Find Paid Clinical Trials in Alabama

Browse Locations ... United States» ... Alabama

Vitamin D Supplementation for Extremely Preterm Infants

Conditions: Vitamin D Deficiency; Preterm Infants; Bronchopulmonary Dysplasia
Interventions: Dietary Supplement: Cholecalciferol; Dietary Supplement: Cholecalciferol; Dietary Supplement: Placebo
Sponsors: University of Alabama at Birmingham; University of Alabama at Birmingham; Children's Health System, Alabama
Not yet recruiting - verified May 2012
An Observational Pilot Study Evaluating The Feasibility of Conducting Genomewide Association Studies Utilizing Subject-Provided Information in Subjects With Metastatic Breast Cancer Treated With Avastin (Bevacizumab)

Condition: Breast Cancer
Intervention:
Sponsors: Genentech; Genentech; 23andMe, Inc.
Recruiting - verified May 2012
Safety and Efficacy Study of Single-Dose Oral CEM-101 in Patients With Uncomplicated Urogenital Gonorrhea

Condition: Uncomplicated Urogenital Gonorrhea
Intervention: Drug: solithromycin
Sponsors: Cempra Pharmaceuticals; Cempra Pharmaceuticals
Recruiting - verified May 2012
Safety Study of FluMist With and Without Ampligen

Condition: Influenza, Human
Interventions: Drug: FluMist + Poly I:Poly C12U; Drug: FluMist + Poly I:Poly C12U; Drug: FluMist + Poly I:Poly C12U; Drug: FluMist + Poly I:Poly C12U; Drug: FluMist + Placebo
Sponsors: Hemispherx Biopharma; Hemispherx Biopharma
Recruiting - verified May 2012
Fracture and Bone Mineral Density in HIV+ Patients Recently Started on Antiretroviral Therapy (ART)

Conditions: HIV; Bone Mineral Density; Bone Turnover; Fracture
Intervention:
Sponsors: University of Alabama at Birmingham; University of Alabama at Birmingham
Recruiting - verified May 2012
24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate

Condition: Rheumatoid Arthritis
Interventions: Drug: VX-509; Drug: VX-509 matching placebo
Sponsors: Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals Incorporated
Recruiting - verified May 2012
An Open Label Pilot Study of Adjunctive Asenapine for the Treatment of Posttraumatic Stress Disorder

Condition: Posttraumatic Stress Disorder
Intervention: Drug: Adjunctive asenapine
Sponsors: Tuscaloosa Research & Education Advancement Corporation; Lori Davis, MD; Merck
Not yet recruiting - verified April 2012
Growth of Infants Fed an Amino Acid Infant Formula

Condition: Growth
Interventions: Other: Amino Acid Formula; Other: Amino Acid formula
Sponsors: Nestlé Nutrition Corporate; Nestlé Nutrition Corporate
Not yet recruiting - verified April 2012
Head to Head Study Epi proColon and FIT

Condition: Colorectal Cancer
Intervention:
Sponsors: Epigenomics, Inc; Epigenomics, Inc
Recruiting - verified April 2012
Manual Therapy and Exercise in Patients With Cervicogenic Headache

Condition: Cervicogenic Headache
Interventions: Other: Thrust Manipulation; Other: Non-thrust Mobilization and Exercise
Sponsors: Alabama Physical Therapy & Acupuncture; Alabama Physical Therapy & Acupuncture; Long Island University
Not yet recruiting - verified April 2012
A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications

Condition: Asthma
Interventions: Drug: Fluticasone propionate DPI Dose 1; Drug: Fluticasone propionate DPI Dose 2; Drug: Fluticasone propionate DPI Dose 3; Drug: Fluticasone propionate DPI Dose 4; Other: Placebo DPI; Drug: Flovent Diskus 250 mcg
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries
Recruiting - verified May 2012
Randomized, Double-Blind, Placebo Controlled Study of the Short Term Clinical Effects of Tolvaptan in Patients Hospitalized for Worsening Heart Failure With Challenging Volume Management

Condition: Heart Failure
Interventions: Drug: Tolvaptan or Samsca; Drug: placebo or sugar pill
Sponsors: Cardiovascular Clinical Science Foundation; Cardiovascular Clinical Science Foundation; Otsuka America Pharmaceutical
Not yet recruiting - verified April 2012
A Placebo-controlled Trial of Daliresp on Chronic Obstructive Pulmonary Disease (COPD)

Condition: COPD
Interventions: Drug: roflumilast; Drug: placebo
Sponsors: University of Alabama at Birmingham; University of Alabama at Birmingham
Not yet recruiting - verified April 2012
Phase 2 Study to Evaluate Safety & Efficacy of RM-131 Administered to Patients With Diabetic Gastroparesis

Conditions: Diabetes Mellitus; Diabetes Mellitus Complications; Gastroparesis
Interventions: Drug: RM-131; Drug: Placebo
Sponsors: Rhythm Pharmaceuticals, Inc.; Rhythm Pharmaceuticals, Inc.
Recruiting - verified May 2012
The Safety and Efficacy of AF-219 in Female Subjects With Interstitial Cystitis /Bladder Pain Syndrome

Condition: Bladder Pain Syndrome
Interventions: Drug: AF-219; Drug: Sugar Pill
Sponsors: Afferent Pharmaceuticals, Inc.; Afferent Pharmaceuticals, Inc.
Recruiting - verified April 2012
Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults

Conditions: Acquired Immunodeficiency Syndrome; HIV Infections
Interventions: Drug: darunavir/cobicistat/emtricitabine/GS-7340; Drug: darunavir + cobicistat + emtricitabine/tenofovir df
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified April 2012
Study of the Effect of Fostamatinib Twice Daily on Blood Pressure in Patients With Rheumatoid Arthritis

Condition: Rheumatoid Arthritis
Interventions: Drug: fostamatinib; Drug: placebo
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified April 2012
Characterization of 24-hour Lung Function Profiles of Inhaled Tiotropium + Olodaterol Fixed Dose Combination in Patients Suffering From Chronic Obstructive Pulmonary Disease

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: tiotropium; Drug: tiotropium; Drug: olodaterol; Drug: olodaterol; Drug: olodaterol; Drug: tiotropium; Drug: tiotropium; Drug: olodaterol; Drug: tiotropium
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012
Effect of Postop Steroids on Cardiovascular/Respiratory Function in Neonates Undergoing Cardiopulmonary Bypass

Condition: Heart Disease Congenital Complex
Interventions: Drug: Hydrocortisone; Drug: Normal Saline
Sponsors: University of Alabama at Birmingham; University of Alabama at Birmingham
Recruiting - verified May 2012
A Four-Week Multicenter Study Evaluating the Safety and Efficacy of AF-219 in Subjects With Osteoarthritis of the Knee

Condition: Osteoarthritis of the Knee
Interventions: Drug: AF-219; Drug: Sugar Pill
Sponsors: Afferent Pharmaceuticals, Inc.; Afferent Pharmaceuticals, Inc.
Recruiting - verified April 2012
Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome (Protocol JNJ-27018966IBS3002)

Condition: Irritable Bowel Syndrome
Interventions: Drug: JNJ-27018966; Other: Placebo Comparator
Sponsors: Furiex Pharmaceuticals, Inc; Furiex Pharmaceuticals, Inc
Not yet recruiting - verified May 2012
Post Market Study of the 3DKnee™ With E-plus Insert

Conditions: Osteoarthritis; Traumatic Arthritis; Total Knee Joint Prosthesis
Intervention: Device: 3DKnee™ System with Vitamin E UHMWPE Tibial Inserts
Sponsors: Encore Medical, L.P.; Encore Medical, L.P.; DJO Incorporated
Recruiting - verified May 2012
Pharmacokinetic and Pharmacodynamic Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes

Conditions: Renal Insufficiency, Chronic; Diabetes Mellitus, Type 2
Intervention: Drug: Bardoxolone Methyl
Sponsors: Reata Pharmaceuticals, Inc.; Reata Pharmaceuticals, Inc.
Recruiting - verified May 2012
A Multicenter, Randomized, Open-Label, Parallel-Group Trial to Compare the Efficacy and Safety of the Sufentanil NanoTab PCA System/15 Mcg to Intravenous Patient-Controlled Analgesia With Morphine for the Treatment of Acute Post-Operative Pain

Condition: Post-Operative Pain
Interventions: Drug: Sufentanil NanoTab PCA System/15 mcg; Drug: morphine IV PCA
Sponsors: AcelRx Pharmaceuticals, Inc.; AcelRx Pharmaceuticals, Inc.
Recruiting - verified April 2012
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of the Sufentanil NanoTab PCA System/15 Mcg for the Treatment of Post-Operative Pain in Patients After Open Abdominal Surgery

Condition: Post-Operative Pain
Interventions: Drug: Sufentanil NanoTab PCA System/15 mcg; Drug: Placebo Sufentanil NanoTab PCA System
Sponsors: AcelRx Pharmaceuticals, Inc.; AcelRx Pharmaceuticals, Inc.
Recruiting - verified May 2012
Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors

Conditions: Brain and Central Nervous System Tumors; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Biological: trebananib; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: dynamic contrast-enhanced magnetic resonance imaging
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Clinical Evaluation of the SEQureDx T21 Test In High Risk Pregnancies

Conditions: Down Syndrome; Fetal Aneuploidy
Intervention:
Sponsors: Sequenom, Inc.; Sequenom, Inc.
Recruiting - verified May 2012
A Study to Evaluate the Efficacy and Safety of a Single Application of QUTENZA Compared to That of Placebo in Reducing Pain Intensity in Subjects With Painful Diabetic Peripheral Neuropathy (PDPN)

Conditions: Diabetic Peripheral Neuropathy; Pain
Interventions: Drug: QUTENZA; Drug: Placebo
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc
Recruiting - verified May 2012
A Randomized, Double-Blind and Placebo-Controlled Study of GS-1101 in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: GS-1101 + Rituximab; Drug: Placebo + Rituximab
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified April 2012
A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)

Condition: Rheumatoid Arthritis
Interventions: Biological: PF-05280586; Biological: MabThera; Biological: Rituxan
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012
G551D Observational Study

Condition: Cystic Fibrosis
Intervention:
Sponsors: University of Alabama at Birmingham; Dr. Steven M Rowe
Recruiting - verified March 2012
Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Condition: Rheumatoid Arthritis
Interventions: Biological: Certolizumab Pegol + Methotrexate (MTX); Biological: Placebo + Methotrexate (MTX)
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified May 2012
Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab

Condition: Psoriasis
Intervention: Drug: etanercept
Sponsors: Amgen; Amgen
Recruiting - verified April 2012
Linaglitpin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: metformin; Drug: linagliptin; Drug: linagliptin medium dose; Drug: metformin placebo; Drug: metformin placebo
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified May 2012
A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease

Condition: Cardiovascular Disease, Coronary Heart Disease, Dyslipidemia, Peripheral Arterial Disease (PAD)
Interventions: Drug: dalcetrapib; Drug: Placebo; Other: Background care
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012
Combining Lesinurad With Allopurinol in Inadequate Responders

Condition: Gout
Interventions: Drug: Lesinurad; Drug: Lesinurad; Drug: Placebo
Sponsors: Ardea Biosciences, Inc.; Ardea Biosciences, Inc.
Recruiting - verified May 2012
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors

Condition: Gout
Interventions: Drug: lesinurad; Drug: Placebo
Sponsors: Ardea Biosciences, Inc.; Ardea Biosciences, Inc.
Recruiting - verified May 2012
Efficacy and Safety of Targeted Intramyocardial Delivery of Auto CD34+ Stem Cells for Improving Exercise Capacity in Subjects With Refractory Angina

Conditions: Chronic Myocardial Ischemia; Refractory Angina Pectoris; (Advanced) Coronary Heart Disease
Interventions: Biological: Auto-CD34+ cells; Biological: Placebo: Diluent used to suspend Auto-CD34+ cells; Other: Standard of care
Sponsors: Baxter Healthcare Corporation; Baxter Healthcare Corporation
Recruiting - verified April 2012
Safety and Efficacy Study of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution to Treat Non-Infectious Anterior Segment Uveitis

Condition: Anterior Uveitis
Interventions: Drug: 40 mg/mL Dexamethasone phosphate ophthalmic solution; Drug: Prednisolone Acetate (1%) Eyedrops; Drug: 100 mM sodium citrate buffer solution; Drug: Placebo Eyedrops
Sponsors: Eyegate Pharmaceuticals, Inc.; Eyegate Pharmaceuticals, Inc.
Recruiting - verified May 2012
A Safety Study of 3 Different Bowel Cleansing Preparations

Conditions: Colonoscopy; Bowel Preparation; Endoscopy
Interventions: Drug: PEG-3350 based bowel preparation; Drug: BLI800 approved preparation regimen; Drug: BLI800 investigational preparation regimen
Sponsors: Braintree Laboratories; Braintree Laboratories
Recruiting - verified April 2012
Comparison of Efficacy and Safety of TachoSil® Versus Surgicel® Original for the Secondary Hemostatic Treatment in Vascular Surgery

Condition: Bleeding
Interventions: Drug: TachoSil®; Drug: Surgicel® Original
Sponsors: Nycomed; Nycomed; Baxter US
Recruiting - verified April 2012
A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma

Conditions: Glioblastoma; Small Cell Glioblastoma; Giant Cell Glioblastoma; Gliosarcoma; Glioblastoma With Oligodendroglial Component; Recurrent Glioblastoma; Relapsed Glioblastoma
Interventions: Drug: Bevacizumab; Drug: Rindopepimut (CDX-110) with GM-CSF; Drug: KLH
Sponsors: Celldex Therapeutics; Celldex Therapeutics
Recruiting - verified May 2012
The Childhood and Adolescent Migraine Prevention Study

Conditions: Migraine; Migraine Disorders; Headache
Interventions: Drug: Amitriptyline; Drug: Topiramate; Drug: Placebo
Sponsors: Children's Hospital Medical Center, Cincinnati; Children's Hospital Medical Center, Cincinnati; National Institute of Neurological Disorders and Stroke (NINDS)
Not yet recruiting - verified April 2012
A Study to Evaluate the Efficacy and Safety of VX-765 in Subjects With Treatment-Resistant Partial Epilepsy

Condition: Epilepsy
Interventions: Drug: VX-765 Part A; Drug: Placebo; Drug: VX-765 Part B
Sponsors: Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals Incorporated
Recruiting - verified May 2012
Phase 3 Papulopustular Rosacea Study

Condition: Papulopustular Rosacea (PPR)
Interventions: Drug: CD5024; Drug: Azelaic acid 15% Gel
Sponsors: Galderma; Galderma
Recruiting - verified April 2012
Combining Lesinurad With Allopurinol in Inadequate Responders

Condition: Gout
Interventions: Drug: Lesinurad; Drug: Lesinurad; Drug: Placebo
Sponsors: Ardea Biosciences, Inc.; Ardea Biosciences, Inc.
Recruiting - verified May 2012
Randomized Placebo Controlled Trial of Budesonide MMX® 9 mg in Patients With Ulcerative Colitis Currently on a 5-ASA

Condition: Ulcerative Colitis
Interventions: Drug: Budesonide; Drug: Placebo; Procedure: Procedure/Surgery: Blood sampling, endoscopy
Sponsors: Santarus; Santarus
Recruiting - verified May 2012
A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome

Condition: Irritable Bowel Syndrome
Interventions: Drug: 250 mg LX1033 tablets; Drug: Placebo tablet
Sponsors: Lexicon Pharmaceuticals; Lexicon Pharmaceuticals
Recruiting - verified April 2012
Study Comparing BMS-790052 (Daclatasvir) to Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Untreated Hepatitis C Patients

Condition: Hepatitis C
Interventions: Drug: BMS-790052 (Daclatasvir); Drug: Telaprevir; Drug: Peginterferon alfa-2a; Drug: Ribavirin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified February 2012
A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Condition: Atrial Fibrillation
Interventions: Drug: Pradaxa (dabigatran etexilate); Drug: Pradaxa (dabigatran etexilate); Drug: Pradaxa, within 30 minutes after a meal; Drug: pantoprazole
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012
AMR-001 Versus Placebo Post ST Segment Elevation Myocardial Infarction

Condition: ST Segment Elevation Myocardial Infarction
Interventions: Biological: AMR-001; Other: placebo
Sponsors: Amorcyte, Inc.; Amorcyte, Inc.
Recruiting - verified December 2011
A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer

Condition: Breast Cancer
Interventions: Drug: pertuzumab; Drug: trastuzumab; Drug: Aromatase Inhibitor; Drug: Induction Chemotherapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012
Open-Label Non-Inferiority Study Evaluating the Efficacy and Safety of Xeomin® in Subjects With Cervical Dystonia Flex

Condition: Cervical Dystonia
Intervention: Biological: Xeomin®
Sponsors: Merz Pharmaceuticals, LLC; Merz Pharmaceuticals, LLC
Recruiting - verified May 2012
Thoratec's Reduce Driveline Trauma Through Stabilization and Exit Site Management Study

Conditions: Left Ventricular Assist Device; Percutaneous Lead Management
Intervention: Other: Percutaneous Lead Management Kit
Sponsors: Thoratec Corporation; Thoratec Corporation
Not yet recruiting - verified April 2012
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Condition: Relapsing-remitting Multiple Sclerosis
Intervention:
Sponsors: Biogen Idec; Biogen Idec
Recruiting - verified May 2012
An Efficacy and Safety Study of Ixmyelocel-T in Patients With Critical Limb Ischemia (CLI)

Condition: Critical Limb Ischemia
Interventions: Biological: Ixmyelocel-T; Other: Vehicle Control
Sponsors: Aastrom Biosciences; Aastrom Biosciences
Recruiting - verified May 2012
Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial

Condition: Hepatitis C
Intervention: Drug: Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified April 2012
A Study of Ritonavir-Boosted Danoprevir and RO5024048 in Different Combinations in Null Responder or Treatment-Naïve Patients With Chronic Hepatitis C and Compensated Cirrhosis

Condition: Hepatitis C, Chronic
Interventions: Drug: danoprevir; Drug: ritonavir; Drug: RO5024048; Drug: peginterferon alfa-2a [Pegasys]; Drug: ribavirin
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012
A Study of Mericitabine in Combination With Telaprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C

Condition: Hepatitis C, Chronic
Interventions: Drug: mericitabine; Drug: mericitabine; Drug: Placebo; Drug: Placebo; Drug: Pegasys; Drug: Copegus; Drug: Pegasys; Drug: Copegus; Drug: telaprevir
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012
Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection

Conditions: HIV Infections; Hepatitis C
Interventions: Drug: Pegylated-Interferon Alfa 2b (PEG-IFN); Drug: Ribavirin (RBV); Drug: Boceprevir (BOC)
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified May 2012
Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: TAK-875; Drug: TAK-875; Drug: Glimepiride
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Global Research & Development Center, Inc.
Recruiting - verified May 2012
TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy

Condition: Hepatitis C
Interventions: Drug: TMC435; Drug: TVR
Sponsors: Janssen R&D Ireland; Janssen R&D Ireland
Recruiting - verified April 2012
Intramuscular Injections of Degarelix Administered in 1-Month Dosing Regimens in Patients With Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: Degarelix
Sponsors: Ferring Pharmaceuticals; Ferring Pharmaceuticals
Recruiting - verified April 2012
Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma

Conditions: Glioblastoma; Small Cell Glioblastoma; Giant Cell Glioblastoma; Gliosarcoma; Glioblastoma With Oligodendroglial Component
Interventions: Drug: Rindopepimut (CDX-110) with GM-CSF; Drug: Temozolomide; Drug: KLH
Sponsors: Celldex Therapeutics; Celldex Therapeutics
Recruiting - verified May 2012
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)

Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Sitagliptin; Drug: Atorvastatin; Other: Placebo to sitagliptin; Other: Placebo to atorvastatin; Drug: Metformin; Drug: Glimepiride; Drug: Placebo to glimepiride
Sponsors: Merck; Merck
Recruiting - verified May 2012
Study of Heart Failure Hospitalizations After Aquapheresis Therapy Compared to Intravenous (IV) Diuretic Treatment

Conditions: Heart Failure; Cardiac Failure; Acute Decompensated Heart Failure (ADHF)
Interventions: Device: Aquadex FlexFlow System; Drug: IV Loop Diuretics (LD)
Sponsors: Gambro Renal Products, Inc.; Gambro Renal Products, Inc.; Gambro UF Solutions, Inc.
Recruiting - verified May 2012
A Multiple Dose Study Of PD-0360324 In Patients With Active Cutaneous Lupus Erythematosus

Condition: Cutaneous Lupus Erythematosus
Interventions: Drug: PD-0360324; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)

Conditions: Generalized Anxiety Disorder (GAD); Anxiety, Separation; Phobia, Social
Interventions: Drug: SPD503 (extended-release Guanfacine hydrochloride); Drug: Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified April 2012
A Study in Participants With Type 2 Diabetes Mellitus

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: LY2605541; Drug: Insulin Glargine; Drug: Insulin Lispro
Sponsors: Eli Lilly and Company; Eli Lilly and Company; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified April 2012
Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: paclitaxel; Drug: pazopanib hydrochloride; Other: placebo
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus

Condition: Hepatitis C, Genotype 1
Interventions: Drug: BMS-790052 (Daclatasvir); Drug: Ribavirin; Drug: Peg-Interferon alfa 2a
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified April 2012
A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)

Condition: Hepatitis C
Interventions: Drug: Telaprevir; Drug: Ribavirin; Biological: peginterferon alfa-2a
Sponsors: Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals Incorporated
Recruiting - verified May 2012
Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma

Condition: Lymphoma
Interventions: Drug: alisertib; Genetic: fluorescence in situ hybridization; Genetic: microarray analysis; Genetic: mutation analysis; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2012
Telaprevir in Combination With Peginterferon and Ribavirin in Treatment-experienced Black/African American Subjects.

Condition: Hepatitis C
Interventions: Drug: Telaprevir; Drug: ribavirin; Biological: peginterferon alfa-2a; Drug: ribavirin; Biological: peginterferon alfa-2a; Drug: ribavirin; Biological: peginterferon alfa-2a
Sponsors: Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals Incorporated
Recruiting - verified May 2012
Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With Implantable Cardioverter Defibrillators (ICDs)

Conditions: Arrhythmias, Cardiac; Heart Diseases; Cardiovascular Diseases; Implantable Cardioverter Defibrillator
Interventions: Drug: Azimilide Dihydrochloride; Drug: Placebo
Sponsors: Forest Laboratories; Forest Laboratories
Recruiting - verified May 2012
Observational Study of the Use of KRYSTEXXA® in Refractory Chronic Gout

Condition: Chronic Gout
Intervention: Biological: pegloticase
Sponsors: Savient Pharmaceuticals; Savient Pharmaceuticals
Recruiting - verified May 2012
The Pharmacokinetics of Azithromycin Prophylaxis for Cesarean Delivery

Condition: Endometritis
Intervention: Drug: Azithromycin
Sponsors: University of Alabama at Birmingham; University of Alabama at Birmingham
Recruiting - verified April 2012
Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia

Condition: Leukemia, Pediatric
Intervention: Drug: Dasatinib
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Children's Oncology Group; EsPhALL - European Intergroup Study on Post Induction Treatment of Philadelphia Positive Acute Lymphoblastic Leukaemia with Imatinib
Recruiting - verified April 2012
Efficacy of a 12-week Regimen of Telaprevir, Peginterferon, and Ribavirin in Subjects With Interleukin-28B (IL28B) CC Genotype in Treatment-naive and Prior Relapser Subjects

Condition: Hepatitis C, Chronic
Interventions: Drug: telaprevir; Drug: Peginterferon alfa-2a; Drug: ribavirin
Sponsors: Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals Incorporated
Recruiting - verified May 2012
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

Conditions: Acute Lymphoid Leukemia; Acute Myeloid Leukemia; Chronic Lymphocytic Leukemia; Multiple Myeloma; Solid Tumors
Intervention: Drug: brentuximab vedotin
Sponsors: Seattle Genetics, Inc.; Seattle Genetics, Inc.
Recruiting - verified April 2012
A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis

Condition: Ulcerative Colitis
Interventions: Drug: CP-690,550; Drug: CP-690,550; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
Long-Term Study Of CP-690,550 In Subjects With Ulcerative Colitis

Condition: Ulcerative Colitis
Interventions: Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Not yet recruiting - verified May 2012
A Study Of Oral CP-690550 As A Maintenance Therapy For Ulcerative Colitis

Condition: Ulcerative Colitis
Interventions: Drug: Placebo; Drug: CP690,550; Drug: CP690,550
Sponsors: Pfizer; Pfizer
Not yet recruiting - verified May 2012
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis

Condition: Multiple Sclerosis
Interventions: Drug: Ofatumumab 3mg; Drug: Ofatumumab 30mg; Drug: Ofatumumab 60mg; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012
Comparison of TAK-875 With Placebo in Participants With Type 2 Diabetes

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: TAK-875; Drug: TAK-875
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Global Research & Development Center, Inc.
Recruiting - verified May 2012
Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)

Condition: Paroxysmal Atrial Fibrillation
Interventions: Device: EAS-AC (HeartLight); Procedure: Control Arm Ablation
Sponsors: CardioFocus; CardioFocus
Recruiting - verified April 2012
AMG 151 Amgen Protocol Number 20100761

Condition: Diabetes Mellitus
Intervention: Drug: AMG 151
Sponsors: Amgen; Amgen
Recruiting - verified April 2012
Study Evaluating The Safety And Efficacy Of Varenicline and Bupropion For Smoking Cessation In Subjects With And Without A History Of Psychiatric Disorders

Condition: Smoking Cessation
Interventions: Drug: Placebo; Drug: varenicline tartrate; Drug: bupropion hydrochloride; Drug: Nicotine Replacement Therapy Patch
Sponsors: Pfizer; Pfizer; GlaxoSmithKline
Recruiting - verified May 2012
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis

Conditions: Gastroparesis; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: 10mg TZP-102; Drug: 20mg TZP-102
Sponsors: Tranzyme, Inc.; Tranzyme, Inc.
Recruiting - verified April 2012
A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Condition: Diffuse Large B-Cell Lymphoma (DLBCL)
Interventions: Drug: MEDI-551; Drug: Rituximab; Drug: ICE; Drug: DHAP; Procedure: Autologous Stem Cell Transplant (ASCT)
Sponsors: MedImmune LLC; MedImmune LLC
Recruiting - verified April 2012
A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to MCV4, Tdap and rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 10 Through 12 Years of Age

Conditions: Vaccines; Meningococcal Vaccines
Interventions: Biological: rLP2086 + MCV4 + Tdap; Biological: MCV4 + Tdap + saline; Biological: rLP2086 + saline
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012
Open Label Study of Long Term Evaluation Against LDL-C Trial (OSLER)

Condition: Hypercholesterolemia
Interventions: Drug: AMG 145 and standard of care; Other: Standard of care
Sponsors: Amgen; Amgen
Recruiting - verified April 2012
Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI)

Conditions: Coronary Artery Disease; Angina Pectoris
Interventions: Drug: Ranolazine; Drug: Placebo
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified April 2012
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder

Condition: Major Depressive Disorder
Interventions: Drug: SPD489 (Lisdexamfetamine dimesylate ); Drug: Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified May 2012
Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung Cancer

Conditions: Non-small Cell Lung Cancer (NSCLC); Stage IV NSCLC; Metastatic NSCLC
Interventions: Drug: Cabazitaxel-XRP6258; Drug: Cabazitaxel-XRP6258
Sponsors: University of Alabama at Birmingham; University of Alabama at Birmingham; Sanofi-Aventis
Recruiting - verified April 2012
Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: tiotropium; Drug: olodaterol; Drug: tiotropium; Drug: tiotropium + olodaterol
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012
Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy

Condition: Breast Cancer
Interventions: Drug: fulvestrant; Drug: GDC-0941; Drug: GDC-0980; Drug: placebo
Sponsors: Genentech; Genentech
Recruiting - verified April 2012
The Plecanatide Chronic Idiopathic Constipation (CIC) Study

Condition: Chronic Idiopathic Constipation
Intervention: Drug: plecanatide
Sponsors: Synergy Pharmaceuticals, Inc.; Synergy Pharmaceuticals, Inc.; PAREXEL International
Recruiting - verified April 2012
Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials

Condition: Hepatitis C Virus
Interventions: Drug: BMS-790052 (HCV NS5A Replication Co-factor Inhibitor); Drug: BMS-650032 (HCV NS3 Protease Inhibitor); Drug: Peginterferon alfa-2a; Drug: Ribavirin; Drug: Ribavirin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified February 2012
A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Patients With Breast Cancer

Condition: Breast Cancer
Interventions: Biological: Ramucirumab (IMC-1121B); Drug: Eribulin
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified May 2012
Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) for Uncontrolled Moderate - Severe Low Back Pain

Condition: Low Back Pain
Interventions: Drug: Oxycodone/Naloxone controlled-release; Drug: Oxycodone HCl controlled-release; Drug: Placebo
Sponsors: Purdue Pharma LP; Purdue Pharma LP
Recruiting - verified May 2012
A Study of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain

Condition: Low Back Pain
Interventions: Drug: Oxycodone/Naloxone controlled-release; Drug: Oxycodone HCl controlled-release; Drug: Placebo
Sponsors: Purdue Pharma LP; Purdue Pharma LP
Recruiting - verified May 2012
Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients

Condition: Acute Gouty Arthritis
Intervention: Drug: Canakinumab 150mg in prefilled syringe
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Baby Observational and Nutritional Study

Conditions: Cystic Fibrosis; Growth Failure
Intervention:
Sponsors: Ramsey, Bonnie, MD; Ramsey, Bonnie, MD; Cystic Fibrosis Foundation
Recruiting - verified May 2012
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: BI 10773; Drug: BI 10773; Drug: BI 10773; Drug: linagliptin; Drug: BI 10773 linagliptin FDC; Drug: BI 10773 linagliptin FDC; Drug: high dose BI 10773 placebo; Drug: high dose BI 10773 placebo; Drug: high dose BI 10773 placebo; Drug: low dose BI 10773 placebo; Drug: low dose BI 10773 placebo; Drug: low dose BI 10773 placebo; Drug: linagliptin; Drug: linagliptin; Drug: high dose FDC placebo; Drug: high dose FDC placebo; Drug: high dose FDC placebo; Drug: high dose FDC placebo; Drug: low dose FDC placebo; Drug: low dose FDC placebo; Drug: low dose FDC placebo; Drug: linagliptin placebo; Drug: linagliptin placebo; Drug: linagliptin placebo; Drug: BI 10773; Drug: BI 10773 high dose; Drug: BI 10773 low dose
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified May 2012
Major Depressive Disorder With Mixed Features - Extension

Condition: Major Depressive Disorder
Intervention: Drug: Lurasidone
Sponsors: Sunovion; Sunovion
Recruiting - verified April 2012
A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents

Condition: Meningococcal Meningitis
Interventions: Biological: placebo+ Combined Tetanus, Reduced Diphtheria Toxoid Acellular Pertussis Vaccine+Quadrivalent Human Papillomavirus Vaccine; Biological: MenACWY Conjugate Vaccine+Combined Tetanus, Reduced Diphtheria Toxoid,Acellular Pertussis Vaccine +Quadrivalent Human Papillomavirus Vaccine
Sponsors: Novartis; Novartis; Novartis Vaccines
Recruiting - verified April 2012
Study of Ruxolitinib in Pancreatic Cancer Patients

Condition: Metastatic Pancreatic Adenocarcinoma
Interventions: Drug: Number 1 - Capecitabine and ruxolitinib; Drug: Number 2 - Capecitabine and placebo
Sponsors: Incyte Corporation; Incyte Corporation
Recruiting - verified May 2012
A Study of Brentuximab Vedotin in Patients With CD30-positive Non-Hodgkin Lymphoma

Conditions: Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell
Intervention: Drug: brentuximab vedotin
Sponsors: Seattle Genetics, Inc.; Seattle Genetics, Inc.
Recruiting - verified April 2012
A Study Of Two Dual PI3K/mTOR Inhibitors, PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial Cancer

Condition: Endometrial Neoplasms
Interventions: Drug: PF-04691502; Drug: PF-05212384; Drug: PF-04691502; Drug: PF-05212384
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
Major Depressive Disorder (MDD) With Mixed Features - Flexible Dose

Condition: Major Depressive Disorder With Mixed Features
Interventions: Drug: Lurasidone; Drug: Placebo
Sponsors: Sunovion; Sunovion
Recruiting - verified April 2012
Renal Denervation in Patients With Uncontrolled Hypertension (SYMPLICITY HTN-3)

Condition: Uncontrolled Hypertension
Intervention: Device: Renal denervation (Symplicity Catheter System)
Sponsors: Medtronic Vascular; Medtronic Vascular
Recruiting - verified May 2012
Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer

Conditions: Cervical Cancer; Chemotherapeutic Agent Toxicity; Cognitive/Functional Effects; Psychosocial Effects of Cancer and Its Treatment; Radiation Toxicity; Sexuality and Reproductive Issues
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer

Conditions: Prostatic Neoplasm; Prostate Cancer; Prostatic Adenocarcinoma
Interventions: Biological: sipuleucel-T; Drug: leuprolide acetate
Sponsors: Dendreon; Dendreon
Recruiting - verified May 2012
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia

Conditions: Cognitive/Functional Effects; Leukemia; Neurotoxicity; Pain; Therapy-related Toxicity
Interventions: Drug: clofarabine; Drug: cyclophosphamide; Drug: cytarabine; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: hydrocortisone sodium succinate; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: thioguanine; Drug: vincristine sulfate; Radiation: selective external radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Observational Study in Patients With Autosomal Dominant Polycystic Kidney Disease

Condition: Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Intervention:
Sponsors: Otsuka Pharmaceutical Development & Commercialization, Inc.; Otsuka Pharmaceutical Development & Commercialization, Inc.; Otsuka Pharmaceutical Co., Ltd.
Recruiting - verified May 2012
Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma

Conditions: Leukemia; Lymphoma
Interventions: Drug: dexamethasone; Drug: methotrexate; Drug: mitoxantrone hydrochloride; Drug: pegaspargase; Drug: temsirolimus; Drug: vincristine sulfate; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Phase III Trial of BI 201335 in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)- Human Immunodeficiency Virus (HIV) Coinfected Patients

Condition: Hepatitis C, Chronic
Interventions: Drug: BI201335; Drug: BI201335 24W; Drug: PegIFN/RBV; Drug: PegIFN/RBV
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer

Conditions: Colorectal Neoplasms; Digestive System Diseases; Colonic Diseases; Colorectal Cancer
Intervention:
Sponsors: Exact Sciences Corporation; Exact Sciences Corporation
Recruiting - verified August 2011
Study to Evaluate the Safety and Efficacy of JVS-100 Administered to Adults With Critical Limb Ischemia

Condition: Critical Limb Ischemia
Interventions: Biological: JVS-100(4 mg) or placebo/8 injections; Biological: JVS-100(8 mg) or placebo/8 injections; Biological: JVS-100(8 mg) or placebo/16 injections; Biological: JVS-100(16 mg) or placebo/16 injections
Sponsors: Juventas Therapeutics, Inc.; Juventas Therapeutics, Inc.
Recruiting - verified March 2012
A Double-blind Placebo-controlled Study to Evaluate Larazotide Acetate for the Treatment of Celiac Disease

Condition: Celiac Disease
Interventions: Drug: Larazotide Acetate 0.5 mg; Drug: Larazotide Acetate 1 mg; Drug: Larazotide Acetate 2 mg; Drug: placebo
Sponsors: Alba Therapeutics; Alba Therapeutics; Teva Pharmaceuticals USA
Recruiting - verified July 2011
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

Conditions: Cardiovascular Disease; Diabetes Mellitus, Type 2
Interventions: Drug: Dulaglutide; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012
Extension to CQTI571A2102 to Evaluate Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension

Condition: Pulmonary Arterial Hypertension
Intervention: Drug: Imatinib
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program

Condition: Pulmonary Arterial Hypertension
Intervention:
Sponsors: Actelion; Actelion; Canadian Heart Research Centre
Recruiting - verified April 2012
BMS-790052 Plus Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Black/African-Americans, Latinos and White/Caucasians With Hepatitis C

Condition: Hepatitis C
Interventions: Drug: BMS-790052 (NS5A Replication Complex Inhibitor); Drug: Peg-Interferon Alfa-2a; Drug: Ribavirin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified December 2011
Omega-3-Fatty Acid Supplements in Treating Muscle and Bone Pain and Stiffness in Patients With Stage I, Stage II, or Stage III Breast Cancer Receiving Hormone Therapy

Conditions: Arthralgia; Breast Cancer; Pain
Interventions: Dietary Supplement: omega-3 fatty acid; Other: placebo
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
MRD Testing Before and After Hematopoietic Cell Transplantation Transplantation for Pediatric Acute Myeloid Leukemia

Condition: Acute Myeloid Leukemia
Intervention:
Sponsors: Center for International Blood and Marrow Transplant Research; Center for International Blood and Marrow Transplant Research; Resource for Clinical Investigations in Blood and Marrow Transplantation (RCI-BMT); Pediatric Blood and Marrow Transplant Consortium
Recruiting - verified May 2012
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)

Condition: Rheumatoid Arthritis
Interventions: Drug: rituximab [MabThera/Rituxan]; Drug: methotrexate
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012
Safety Study of AMG 557 in Subjects With Subacute Cutaneous Lupus Erythematosus

Conditions: Cutaneous Lupus; Lupus
Interventions: Drug: AMG 557; Drug: AMG 557 Placebo
Sponsors: Amgen; Amgen
Recruiting - verified April 2012
A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy

Conditions: Metastatic ER+ Her2- Breast Cancer; Postmenopausal
Interventions: Drug: Exemestane; Drug: Abiraterone acetate + Prednisone/ Prednisolone + Exemestane; Drug: Abiraterone acetate + Prednisone or Prednisolone
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified April 2012
A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)

Condition: Lambert Eaton Myasthenic Syndrome
Interventions: Drug: Amifampridine Phosphate; Drug: Placebo
Sponsors: BioMarin Pharmaceutical; BioMarin Pharmaceutical
Recruiting - verified May 2012
Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis

Condition: Rheumatoid Arthritis
Interventions: Drug: PF-04171327; Drug: PF-04171327; Drug: PF-04171327; Drug: PF-04171327; Drug: prednisone; Other: prednisone; Other: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
Bortezomib and Sorafenib Tosylate in Patients With Newly Diagnosed Acute Myeloid Leukemia With or Without Mutations

Condition: Leukemia
Interventions: Drug: asparaginase; Drug: bortezomib; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: etoposide; Drug: mitoxantrone hydrochloride; Drug: sorafenib tosylate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD

Condition: Major Depressive Disorder
Interventions: Drug: desvenlafaxine succinate sustained release; Drug: fluoxetine; Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD

Condition: Major Depressive Disorder
Intervention: Drug: DVS SR
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD

Condition: Major Depressive Disorder
Interventions: Drug: Desvenlafaxine Succinate Sustained-Release; Drug: Desvenlafaxine Succinate Sustained-Release; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
A 6-Month Extension Study To The B2061032 Study To Evaluate The Safety, Tolerability, And Efficacy Of DVS SR In The Treatment Of Child And Adolescent Outpatients With MDD

Condition: Major Depressive Disorder
Intervention: Drug: DVS SR
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
Long-Term Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children Who Completed OTR3001

Condition: Pain
Intervention: Drug: Oxycodone hydrochloride controlled-release tablets
Sponsors: Purdue Pharma LP; Purdue Pharma LP
Recruiting - verified May 2012
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression

Condition: Depression
Interventions: Drug: Duloxetine; Drug: Escitalopram; Drug: BMS-820836 Placebo; Drug: BMS-820836; Drug: BMS-820836; Drug: BMS-820836; Drug: BMS-820836
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified August 2011
A Pharmacodynamic Study of Dapoxetine Concomitantly Administered in Participants Taking Terazosin

Condition: Ejaculation
Interventions: Drug: Treatment sequence 2; Drug: Treatment sequence 1
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified April 2012
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression

Condition: Depression
Interventions: Drug: Placebo matching with BMS-820836; Drug: BMS-820836; Drug: BMS-820836; Drug: BMS-820836
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified July 2011
Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer

Conditions: Pain; Advanced Cancer
Interventions: Drug: Sativex®; Drug: Placebo (GA-0034)
Sponsors: GW Pharmaceuticals Ltd.; GW Pharmaceuticals Ltd.; Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified August 2011
Efficacy, Safety and Tolerability of Secukinumab in Patients With Rheumatoid Arthritis Taking Methotrexate

Condition: Rheumatoid Arthritis
Interventions: Biological: secukinumab; Biological: secukinumab; Biological: placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Bipolar Maintenance Study of Lurasidone Adjunctive to Lithium or Divalproex

Condition: Bipolar I Disorder
Interventions: Drug: Lurasidone; Drug: Placebo
Sponsors: Sunovion; Sunovion
Recruiting - verified April 2012
Safety and Efficacy of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients

Condition: Acute Gouty Arthritis
Interventions: Drug: Canakinumab pre-filled syringe; Drug: Canakinumab lyophilized cake; Drug: Triamcinolone Acetonide
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)

Conditions: Muscle Wasting; Non Small Cell Lung Cancer
Interventions: Drug: GTx-024; Drug: placebo
Sponsors: GTx; GTx; Harrison Clinical Research
Recruiting - verified May 2012
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum

Conditions: Muscle Wasting; Non-Small Cell Lung Cancer
Interventions: Drug: GTx-024; Drug: placebo
Sponsors: GTx; GTx; Harrison Clinical Research
Recruiting - verified May 2012
Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Patients

Condition: Pulmonary Arterial Hypertension
Intervention: Drug: Imatinib
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia

Conditions: B Cell Non-Hodgkin's Lymphoma; Chronic Lymphocytic Leukemia; Waldenstrom Macroglobulinemia
Intervention: Drug: AVL-292
Sponsors: Avila Therapeutics; Avila Therapeutics; The Leukemia and Lymphoma Society
Recruiting - verified May 2011
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Conditions: Hematological Malignancies; Certain Lysosomal Storage and Peroxisomal Enzyme Deficiency Disorders; Hurler Syndrome (MPS I); Krabbe Disease (Globoid Leukodystrophy); X-linked Adrenoleukodystrophy; Primary Immunodeficiency Diseases; Bone Marrow Failure; Beta-thalassemia
Intervention: Drug: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
Sponsors: Center for International Blood and Marrow Transplant Research; Center for International Blood and Marrow Transplant Research; National Marrow Donor Program
Recruiting - verified April 2012
A Study of Avastin (Bevacizumab) in Combination With Standard of Care Treatment in Patients With Lung Cancer

Condition: Non-Small Cell Lung Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: Standard of care treatment
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012
Higher-Dose Radiation Therapy or Standard Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery

Condition: Breast Cancer
Interventions: Radiation: 3-dimensional conformal radiation therapy; Radiation: accelerated radiation therapy; Radiation: hypofractionated radiation therapy; Radiation: intensity-modulated radiation therapy; Radiation: whole breast irradiation
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Extension Study of Asenapine {P06107 (NCT01244815)} for Pediatric Bipolar Disorder (P05898 AM2)

Condition: Bipolar Disorder
Intervention: Drug: Asenapine
Sponsors: Schering-Plough; Schering-Plough
Recruiting - verified May 2012
Study of QUADRACEL® Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age

Conditions: Tetanus; Diphtheria; Pertussis; Measles; Polio
Interventions: Biological: Diphtheria and Tetanus Toxoids and Acellular Pertussis + Measles, Mumps, Rubella + Varicella Virus; Biological: Diphtheria and Tetanus Toxoids and Acellular Pertussis + Poliovirus + MMR + Varicella Virus; Biological: Diphtheria and Tetanus Toxoids and Acellular Pertussis + Measles, Mumps, Rubella + Varicella Virus; Biological: Diphtheria and Tetanus Toxoids and Acellular Pertussis + Poliovirus + MMR + Varicella Virus
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012
Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With Ccr5 Tropic HIV 1

Condition: HIV-1
Interventions: Drug: Maraviroc; Drug: Emtricitabine/tenofovir
Sponsors: ViiV Healthcare; ViiV Healthcare; Pfizer
Recruiting - verified May 2012
Evaluation of Ecallantide for Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor Induced Angioedema

Condition: ACE Inhibitor Induced Angioedema
Interventions: Drug: ecallantide; Drug: ecallantide; Drug: ecallantide; Drug: placebo
Sponsors: Dyax Corp.; Dyax Corp.
Recruiting - verified April 2012
Evaluation of 3TC or FTC Mono-therapy Compared to Continuing HAART as a Bridging Strategy

Condition: HIV Disease
Interventions: Drug: HAART regimen; Drug: 3TC or FTC monotherapy
Sponsors: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; International Maternal Pediatric Adolescent AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified May 2012
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients

Condition: Pulmonary Fibrosis
Interventions: Drug: placebo; Drug: BIBF 1120
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone; Biological: Elotuzumab (BMS-901608; HuLuc63); Biological: Elotuzumab (BMS-901608; HuLuc63)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Abbott Biotherapeutics Corp.
Recruiting - verified October 2011
ARCHER 1009 : A Study Of PF-00299804 (Dacomitinib) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer

Condition: Non-Small Cell Lung Cancer (NSCLC)
Interventions: Drug: Dacomitinib (PF-00299804); Drug: Active Comparator (erlotinib)
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
Comparative Effectiveness Study for Bipolar Disorder

Condition: Bipolar Disorder
Interventions: Drug: Lithium; Drug: Quetiapine
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Agency for Healthcare Research and Quality (AHRQ)
Recruiting - verified April 2012
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients

Condition: Hepatitis C
Interventions: Drug: PegIFN/RBV; Drug: BI 201335
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012
Randomized Study of Laser and Balloon Angioplasty Versus Balloon Angioplasty to Treat Peripheral In-stent Restenosis

Condition: Peripheral Arterial Disease
Interventions: Device: Turbo Elite Laser and Turbo Tandem Laser Guide Catheters; Procedure: Balloon angioplasty
Sponsors: Spectranetics Corporation; Spectranetics Corporation
Recruiting - verified April 2012
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Fluticasone Furoate/Vilanterol; Drug: Vilanterol; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012
A Study of RO4905417 in Patients With Non ST-Elevation Myocardial Infarction (Non-STEMI) Undergoing Percutaneous Coronary Intervention

Condition: Myocardial Infarction
Interventions: Drug: RO4905417; Drug: RO4905417; Drug: placebo; Procedure: Percutaneous Coronary Intervention (PCI)
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012
Puberty Related Intervention to Improve Metabolic Outcomes (The PRIMO Study)

Condition: Obesity
Intervention: Other: Macronutrient Modification
Sponsors: University of Alabama at Birmingham; University of Alabama at Birmingham
Recruiting - verified April 2012
A Phase II Study of Efficacy and Safety in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma

Condition: Basal Cell Carcinoma
Intervention: Drug: LDE225
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Condition: Atherosclerosis
Interventions: Drug: Canakinumab; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012
A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study

Condition: Hepatitis C
Intervention: Drug: TMC435
Sponsors: Janssen R&D Ireland; Janssen R&D Ireland
Recruiting - verified April 2012
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Conditions: Central Neuropathic Pain; Multiple Sclerosis
Intervention: Drug: AVP-923
Sponsors: Avanir Pharmaceuticals; Avanir Pharmaceuticals
Recruiting - verified May 2012
Study To Evaluate The Efficacy And Safety Of PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) Taking Salmeterol Xinafoate/Fluticasone Propionate Combination

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: PH-797804; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant

Conditions: Diffuse Large B-cell Lymphoma; de Novo DLBCL; DLBCL Transformed From Indolent Lymphoma; Follicular Grade 3 Lymphoma
Interventions: Drug: Pixantrone + Rituximab; Drug: Gemcitabine + Rituximab
Sponsors: Cell Therapeutics; Cell Therapeutics
Recruiting - verified May 2012
A Study to See if AZLI (an Inhaled Antibiotic) is Effective in Treating Adults With Non-CF Bronchiectasis - AIR-BX2

Condition: Bronchiectasis
Interventions: Drug: Aztreonam for Inhalation Solution (AZLI); Drug: Placebo
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2011
Smoking Cessation Study In Healthy Adolescent Smokers

Condition: Smoking Cessation
Interventions: Drug: Varenicline 1mg BID; Drug: Varenicline 0.5mg BID; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Conditions: Prostate Cancer; Prostatic Neoplasm
Intervention: Drug: abiraterone acetate in combination with prednisone
Sponsors: Janssen Biotech, Inc.; Janssen Biotech, Inc.
Recruiting - verified April 2012
A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis

Condition: Psoriasis
Interventions: Drug: CP-690,550; Drug: CP-690,550; Drug: Placebo/CP-690,550; Drug: Placebo/CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Cabazitaxel (XRP6258); Drug: Prednisone
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012
Caspofungin Acetate or Fluconazole in Preventing Invasive Fungal Infections in Patients With Acute Myeloid Leukemia Who Are Undergoing Chemotherapy

Conditions: Fungal Infection; Leukemia; Neutropenia
Interventions: Drug: caspofungin acetate; Drug: fluconazole
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Study of the Contraceptive Efficacy and Safety of Amphora Gel Compared to Conceptrol Vaginal Gel

Condition: Contraception
Interventions: Drug: Conceptrol; Drug: Amphora
Sponsors: Evofem Inc.; Evofem Inc.; Health Decisions
Recruiting - verified May 2012
Maximum Tolerated Dose Study of Belinostat (PXD-101)in Combination With Paclitaxel Plus Carboplatin in Chemotherapy-Naive Patients With Stage IV Non-Small-Cell Lung Cancer (NSCLC)

Condition: Stage IV Non-small Cell Lung Cancer
Intervention: Drug: Belionstat, Carboplatin, Paclitaxel
Sponsors: Spectrum Pharmaceuticals, Inc; Spectrum Pharmaceuticals, Inc; TopoTarget A/S
Recruiting - verified May 2012
A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia

Condition: Acute Myeloid Leukemia
Interventions: Drug: Sapacitabine and decitabine; Drug: Decitabine
Sponsors: Cyclacel Pharmaceuticals, Inc.; Cyclacel Pharmaceuticals, Inc.
Recruiting - verified November 2011
A 12 Week Study to Confirm the Effectiveness of 8mg of Fesoterodine Compared to 4mg of Fesoterodine

Condition: Overactive Bladder
Interventions: Drug: Fesoterodine 8mg; Drug: Fesoterodine 4mg; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012
A Clinical Study in Patients With Overactive Bladder With Leakage of Urine, to Find Out if the Medicine, Fesoterodine, Works in Those Patients Who Did Not Have Enough Response to the Medicine, Tolterodine.

Conditions: Overactive Bladder; Bladder, Overactive; Overactive Urinary Bladder
Interventions: Drug: Fesoterodine 8 mg; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012
Safety and Efficacy of BI 10773 and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Sitagliptin 100mg; Drug: BI 10773; Drug: BI 10773; Drug: BI 10773; Drug: BI 10773; Drug: BI 10773; Drug: BI 10773; Drug: BI 10773; Drug: BI 10773; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified May 2012
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Condition: Crohn's Disease
Interventions: Drug: PF-04236921 SC injection; Drug: PF-04236921 SC injection; Drug: PF-04236921 SC injection; Drug: PF-04236921 SC injection
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012
A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines

Condition: HIV Infection
Intervention: Drug: Lopinavir/ritonavir (LPV/r)
Sponsors: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; International Maternal Pediatric Adolescent AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Abbott
Recruiting - verified May 2012
Trial Evaluating Xeomin® (incobotulinumtoxinA) for Cervical Dystonia or Blepharospasm in the United States

Conditions: Cervical Dystonia; Blepharospasm
Intervention: Biological: Xeomin®
Sponsors: Merz Pharmaceuticals, LLC; Merz Pharmaceuticals, LLC; Registrat-Mapi
Recruiting - verified May 2012
Pharmacokinetics/Pharmacodynamics Biomarker Study in Active Ulcerative Colitis Patients

Condition: Colitis, Ulcerative
Interventions: Biological: Anrukinzumab; Biological: Anrukinzumab; Biological: Anrukinzumab; Other: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor

Condition: Rheumatoid Arthritis
Interventions: Drug: tocilizumab [RoActemra/Actemra]; Drug: adalimumab; Drug: Placebo; Drug: Placebo; Drug: methotrexate; Drug: folate
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012
Efficacy and Safety Study of CAL-101 in Patients With Indolent B-Cell Non-Hodgkin Lymphoma

Conditions: Indolent Non-Hodgkin Lymphoma; Follicular Lymphoma; Small Lymphocytic Lymphoma; Lymphoplasmacytoid Lymphoma; Marginal Zone Lymphoma
Intervention: Drug: CAL-101
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified April 2012
A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)

Condition: Glioblastoma Multiforme
Interventions: Biological: ICT-107; Biological: Placebo DC
Sponsors: ImmunoCellular Therapeutics, Ltd.; ImmunoCellular Therapeutics, Ltd.
Recruiting - verified May 2012
Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function

Condition: Gastrointestinal Dysmotility
Intervention: Drug: Ipamorelin
Sponsors: Helsinn Therapeutics (U.S.), Inc; Helsinn Therapeutics (U.S.), Inc
Recruiting - verified May 2012
Pediatric Chronic Kidney Disease Safety and Efficacy

Conditions: Chronic Kidney Disease; Hyperparathyroidism; Hyperparathyroidism, Secondary; Kidney Disease; Secondary Hyperparathyroidism
Interventions: Drug: cinacalcet capsule; Drug: placebo capsule; Drug: cinacalcet tablet; Drug: placebo tablet
Sponsors: Amgen; Amgen
Recruiting - verified April 2012
A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis.

Condition: Psoriasis
Interventions: Drug: CP-690,550; Drug: CP-690,550; Drug: Placebo/CP-690,550; Drug: Placebo/CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
Web-based Smoking Cessation Intervention: Transition From Inpatient to Outpatient

Condition: Cigarette Smoking
Intervention: Behavioral: Web-based smoking cessation program
Sponsors: University of Alabama at Birmingham; University of Alabama at Birmingham; National Institute on Drug Abuse (NIDA)
Recruiting - verified May 2012
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III or Stage IV Melanoma That Has Been Removed by Surgery

Condition: Melanoma (Skin)
Interventions: Biological: ipilimumab; Biological: recombinant interferon alfa-2b
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
TMC435-TiDP16-C208 - Phase III Trial of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Patients

Condition: Hepatitis C
Interventions: Drug: Placebo; Drug: TMC435
Sponsors: Janssen R&D Ireland; Janssen R&D Ireland
Recruiting - verified April 2012
Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma

Conditions: Brain and Central Nervous System Tumors; Lymphoma; Lymphoproliferative Disorder; Small Intestine Cancer; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: imetelstat sodium; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Study of the Safety and Efficacy of an Interleukin-6 Inhibitor in Patients With Lupus Nephritis

Conditions: Lupus Nephritis; Kidney Diseases; Kidney Insufficiency; Glomerulonephritis; Systemic Lupus Erythematosus
Interventions: Drug: CNTO 136; Drug: Placebo
Sponsors: Centocor, Inc.; Centocor, Inc.
Recruiting - verified April 2012
TMC435HPC3007 - Phase III Trial of TMC435 in Genotype 1 Hepatitis C-infected Patients Who Relapsed After Previous Therapy

Condition: Hepatitis C
Interventions: Drug: TMC435; Drug: Placebo
Sponsors: Janssen R&D Ireland; Janssen R&D Ireland
Recruiting - verified April 2012
Safety and Immunogenicity of Different Meningitis Vaccine Formulations in Adolescents and Young Adults

Condition: Invasive Meningococcal Disease
Intervention: Biological: Meningococcal ABCWY vaccine
Sponsors: Novartis; Novartis
Recruiting - verified May 2012
Safety and Adherence of a Non-medicated Intravaginal Ring (IVR)

Condition: Healthy
Intervention: Drug: Non-medicated Intravaginal Ring
Sponsors: Population Council; Population Council; National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Mental Health (NIMH); Microbicide Trials Network
Recruiting - verified May 2012
A Trial With TMC278-TIDP6-C222 for Continued TMC278 Access in Patients Infected With Human Immunodeficiency Virus-1

Condition: HIV-1 Infection
Intervention: Drug: Rilpivirine
Sponsors: Janssen R&D Ireland; Janssen R&D Ireland
Recruiting - verified April 2012
A Study of Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer

Condition: Pain
Interventions: Drug: Sativex®; Drug: Placebo (GA-0034)
Sponsors: GW Pharmaceuticals Ltd.; GW Pharmaceuticals Ltd.; Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified May 2011
Manuka Honey in Preventing Esophagitis-Related Pain in Patients Receiving Chemotherapy and Radiation Therapy For Lung Cancer

Conditions: Dysphagia; Lung Cancer; Pain
Interventions: Drug: Manuka honey; Drug: chemotherapy; Other: questionnaire administration; Procedure: adjuvant therapy; Procedure: assessment of therapy complications; Procedure: quality-of-life assessment; Procedure: standard follow-up care; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary Fibrosis

Condition: Idiopathic Pulmonary Fibrosis
Intervention: Drug: FG-3019
Sponsors: FibroGen; FibroGen
Recruiting - verified May 2012
Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus

Condition: Systemic Lupus Erythematosus
Interventions: Drug: Epratuzumab; Drug: Epratuzumab; Drug: Placebo
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified May 2012
Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE)

Condition: Systemic Lupus Erythematosus
Interventions: Drug: Placebo; Drug: Epratuzumab; Drug: Epratuzumab
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified May 2012
A Pilot Study of Lithium in Progressive Multiple Sclerosis

Condition: Multiple Sclerosis
Intervention: Drug: Lithium Carbonate
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified May 2012
Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development Studies

Conditions: Colorectal Neoplasms; Digestive System Diseases; Colonic Diseases; Colorectal Cancer
Intervention:
Sponsors: Exact Sciences Corporation; Exact Sciences Corporation
Recruiting - verified August 2011
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes

Conditions: Renal Insufficiency, Chronic; Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: Bardoxolone Methyl: 20 mg
Sponsors: Reata Pharmaceuticals, Inc.; Reata Pharmaceuticals, Inc.
Recruiting - verified May 2012
Phase 1 and 2 Study of PX-866 and Cetuximab

Conditions: Incurable Metastatic Colorectal Carcinoma; Incurable Progressive, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Interventions: Drug: PX-866 and cetuximab; Drug: Cetuximab; Drug: PX-866 and cetuximab; Drug: Cetuximab
Sponsors: Oncothyreon Inc.; Oncothyreon Inc.
Recruiting - verified April 2012
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Condition: Multiple Sclerosis Relapse
Interventions: Drug: Teriflunomide (HMR1726); Drug: Matching placebo
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: ocrelizumab; Drug: Rebif; Drug: ocrelizumab placebo; Drug: Rebif placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012
Clinical Evaluation of the Blazer® Open-Irrigated Catheter for Treatment of Type 1 Atrial Flutter

Condition: Atrial Flutter
Interventions: Device: Blazer® Open-Irrigated Ablation Catheter; Device: NaviStar™/Celsius™ ThermoCool® or Therapy™ Cool Path™ Ablation Catheter
Sponsors: Boston Scientific Corporation; Boston Scientific Corporation
Recruiting - verified May 2012
A Study of RO4905417 in Patients Undergoing Coronary Artery Bypass Graft (CABG) Surgery

Condition: Coronary Heart Disease, Graft Occlusion, Vascular
Interventions: Drug: RO4905417; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012
Efficacy and Safety of Asenapine Treatment for Pediatric Bipolar Disorder {P06107 Has an Extension (P05898; NCT01349907}(P06107 AM2)

Condition: Bipolar Disorder, Pediatric
Interventions: Drug: asenapine; Drug: Placebo to match asenapine
Sponsors: Schering-Plough; Schering-Plough
Recruiting - verified May 2012
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: glimepride placebo; Drug: linagliptin placebo; Drug: linagliptin; Drug: glimepiride
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified May 2012
Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)

Condition: Polycythemia Vera
Interventions: Drug: INC424 tablets; Other: Best Available Therapy (BAT)
Sponsors: Incyte Corporation; Incyte Corporation; Novartis Pharmaceuticals
Recruiting - verified April 2012
Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer

Condition: Breast Cancer
Interventions: Procedure: palliative surgery; Procedure: therapeutic conventional surgery; Radiation: palliative radiation therapy; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Condition: Chronic Myeloid Leukemia
Intervention:
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; ICON Clinical Research
Recruiting - verified May 2012
A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001 AM2)

Condition: Clostridium Difficile Infection
Interventions: Biological: MK-3415; Biological: MK-6072; Biological: MK-3415A; Biological: Placebo
Sponsors: Merck; Merck
Recruiting - verified May 2012
PH III Relapse or Refractory MM - Open Label With or Without Elotuzumab

Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: Dexamethasone; Drug: Dexamethasone (Oral); Drug: Dexamethasone (IV); Biological: Elotuzumab (BMS-901608; HuLuc63)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Abbott Biotherapeutics Corp.
Recruiting - verified May 2012
Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma

Conditions: Brain and Central Nervous System Tumors; Kidney Cancer; Sarcoma
Interventions: Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: topotecan hydrochloride; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Psychiatric and Antiretroviral Medication Concentrations in HIV-infected and Uninfected Children and Adolescents

Condition: ADHD
Intervention:
Sponsors: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Recruiting - verified May 2012
Topical Metronidazole and Miconazole Co-formulated Vaginal Suppositories for Preventing Vaginal Infections in HIV-seronegative Women

Conditions: Bacterial Vaginosis; Candidiasis; Trichomoniasis
Interventions: Drug: Placebo; Drug: Neo-Penotran® Forte (active ingredient Metronidazole & Miconazole Nitrate)
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified April 2012
A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza.

Conditions: Influenza A Virus, H1N1 Subtype; Influenza, Human; Influenza B Virus; Influenza, Seasonal
Interventions: Drug: 300mg intravenous (IV) zanamivir and oral oseltamivir placebo; Drug: 600mg intravenous (IV) zanamivir and oral oseltamivir placebo; Drug: 75mg oral oseltamivir and intravenous zanamivir placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012
I Change Adherence & Raise Expectations

Condition: Cystic Fibrosis
Interventions: Behavioral: The Medication Adherence Dashboard; Behavioral: Comprehensive Adherence Program
Sponsors: Novartis; Novartis Pharmaceuticals; Genentech; Cystic Fibrosis Foundation
Recruiting - verified May 2012
A Non-drug Study Profiling Asthma

Conditions: Asthma; Health
Intervention: Other: All patients
Sponsors: Centocor, Inc.; Centocor, Inc.
Recruiting - verified April 2012
Alzheimer's Disease Neuroimaging Initiative 2

Conditions: Mild Cognitive Impairment (MCI); Alzheimer's Disease
Intervention:
Sponsors: Alzheimer's Disease Cooperative Study (ADCS); Alzheimer's Disease Cooperative Study (ADCS); Northern California Institute for Research and Education (NCIRE); National Institute on Aging (NIA)
Recruiting - verified May 2012
Everolimus and Octreotide With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery

Conditions: Islet Cell Tumor; Pancreatic Cancer
Interventions: Biological: bevacizumab; Drug: everolimus; Drug: octreotide acetate
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Participants Undergoing Hematopoietic Cell Transplants (HCTs) (Study No. V212-001 AM3)

Condition: Herpes Zoster
Interventions: Biological: V212; Biological: Matching placebo
Sponsors: Merck; Merck
Recruiting - verified May 2012
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases

Conditions: Cognitive/Functional Effects; Metastatic Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Other: laboratory biomarker analysis; Other: questionnaire administration; Procedure: cognitive assessment; Procedure: quality-of-life assessment; Radiation: intensity-modulated radiation therapy; Radiation: whole-brain radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
OPT - Phase IV Long Term Maintenance Study of Aripiprazole for the Treatment of Irritability Associated With Autistic Disorder

Condition: Autistic Disorder
Interventions: Drug: Aripiprazole; Drug: Placebo
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified February 2012
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)

Conditions: Parkinson Disease; Idiopathic Parkinson Disease; Idiopathic Parkinson's Disease
Interventions: Drug: preladenant; Drug: Placebo to preladenant
Sponsors: Schering-Plough; Schering-Plough
Recruiting - verified May 2012
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors

Condition: Breast Cancer
Interventions: Drug: BMS-754807; Drug: letrozole
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Mayo Clinic
Recruiting - verified December 2011
Vinorelbine Ditartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma

Condition: Sarcoma
Interventions: Biological: bevacizumab; Drug: cyclophosphamide; Drug: temsirolimus; Drug: vinorelbine tartrate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Study the Effects of Ranolazine on Myocardial Perfusion Assessed by Serial Quantitative Exercise SPECT Imaging

Conditions: Myocardial Perfusion Imaging; Myocardial Ischemia
Interventions: Drug: Placebo; Drug: Ranolazine
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified April 2012
Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer

Conditions: Prostate Neoplasms; Genital Neoplasms, Male; Urogenital Neoplasms; Genital Diseases, Male
Intervention: Drug: Abiraterone Acetate
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Available - verified April 2012
Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors

Condition: Brain and Central Nervous System Tumors
Interventions: Biological: bevacizumab; Drug: irinotecan hydrochloride; Drug: temozolomide
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
An Open Label Study for Patients With Rheumatoid Arthritis

Condition: Rheumatoid Arthritis
Intervention: Drug: LY2127399
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2012
Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke

Condition: Ischemic Stroke
Interventions: Drug: PF-03049423; Drug: PF-03049423; Drug: PF-03049423; Other: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
A Two-Part, 12-Week Study of Etoricoxib as a Treatment for Rheumatoid Arthritis (RA) (MK-0663-107)

Condition: Arthritis, Rheumatoid
Interventions: Drug: Part 1: Etoricoxib 60 mg; Drug: Part 1: Etoricoxib 90 mg; Drug: Part 2: Etoricoxib 60 mg; Drug: Part 2: Etoricoxib 90 mg; Drug: Part 1: Placebo to Etoricoxib 60 mg; Drug: Part 1: Placebo to Etoricoxib 90 mg; Drug: Part 2: Placebo to Etoricoxib 60 mg; Drug: Part 2: Placebo to Etoricoxib 90 mg
Sponsors: Merck; Merck
Recruiting - verified May 2012
Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes

Condition: Type 2 Diabetes
Interventions: Drug: Saxagliptin; Drug: Placebo (Saxagliptin); Drug: Metformin IR; Drug: Placebo (Metformin); Drug: Metformin (Active Rescue)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; AstraZeneca
Recruiting - verified February 2012
Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial

Condition: Acute Coronary Syndrome
Interventions: Drug: Placebo; Drug: CER-001
Sponsors: Cerenis Therapeutics, SA; Cerenis Therapeutics, SA
Recruiting - verified May 2012
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer

Conditions: Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer
Interventions: Biological: trastuzumab; Drug: carboplatin; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Condition: Type 2 Diabetes
Interventions: Drug: Dapagliflozin; Drug: Placebo matching Dapagliflozin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; AstraZeneca
Recruiting - verified November 2011
Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use NSAIDs and/or Colchicine.

Condition: Acute Gout
Intervention: Drug: ACZ885
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Oronasopharyngeal Suction Versus Simple Nose and Mouth Wiping in Term Newborns

Conditions: Childbirth; Resuscitation
Interventions: Procedure: Bulb Suctioning; Procedure: Wiping
Sponsors: University of Alabama at Birmingham; University of Alabama at Birmingham
Recruiting - verified April 2012
Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children With Moderate to Severe Malignant and/ or Nonmalignant Pain Requiring Opioids

Condition: Pain
Intervention: Drug: Oxycodone HCl controlled-release tablets
Sponsors: Purdue Pharma LP; Purdue Pharma LP
Recruiting - verified May 2012
Risk-Adapted Chemotherapy in Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: thioguanine; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Flexible Dose, Long-term Safety Study of Asenapine for the Treatment of Schizophrenia in Adolescents (P05897 AM2 EXT)

Conditions: Schizophrenia, Paranoid; Schizophrenia, Disorganized; Schizophrenia, Undifferentiated
Intervention: Drug: asenapine
Sponsors: Schering-Plough; Schering-Plough
Recruiting - verified May 2012
Fixed Dose Efficacy and Safety Study of Asenapine for the Treatment of Schizophrenia in Adolescents (P05896 AM2)

Conditions: Schizophrenia, Paranoid; Schizophrenia, Disorganized; Schizophrenia, Undifferentiated
Interventions: Drug: asenapine; Drug: asenapine; Drug: placebo BID
Sponsors: Schering-Plough; Schering-Plough
Recruiting - verified May 2012
A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis

Condition: Psoriasis
Interventions: Drug: CP-690,550; Drug: CP-690,550; Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012
A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Condition: Crohn's Disease
Interventions: Biological: Infliximab; Drug: Placebo
Sponsors: Janssen Biotech, Inc.; Janssen Biotech, Inc.
Recruiting - verified April 2012
Safety and Effectiveness of World Health Organization Dosing Guidelines of Lopinavir/Ritonavir for Children

Condition: HIV
Intervention: Drug: Lopinavir/ritonavir
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2012
Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-line Metastatic Soft Tissue Sarcoma

Condition: Soft Tissue Sarcoma
Interventions: Drug: doxorubicin in combination with palifosfamide-tris; Drug: doxorubicin in combination with placebo
Sponsors: ZIOPHARM; ZIOPHARM
Recruiting - verified April 2012
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis

Condition: Psoriasis
Interventions: Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012
MLN8237 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia

Conditions: Brain and Central Nervous System Tumors; Childhood Germ Cell Tumor; Kidney Cancer; Leukemia; Liver Cancer; Neuroblastoma; Sarcoma
Interventions: Drug: alisertib; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast Cancer

Condition: Her2 Negative Breast Cancer Patients
Interventions: Drug: MM-121 (SAR256212) and Exemestane; Drug: Placebo and Exemestane
Sponsors: Merrimack Pharmaceuticals; Merrimack Pharmaceuticals
Recruiting - verified May 2012
Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)

Condition: Acute Coronary Syndrome
Interventions: Drug: lixisenatide (AVE0010); Drug: placebo
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012
Home-Based Automated Therapy of Arm Function After Stroke Via Tele-Rehabilitation

Condition: Stroke
Interventions: Behavioral: Tele-AutoCITE; Behavioral: CI therapy
Sponsors: University of Alabama at Birmingham; University of Alabama at Birmingham; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified April 2012
Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine

Condition: Meningococcal Meningitis
Interventions: Biological: Meningococcal ACWY conjugate vaccine; Biological: Meningococcal ACWY conjugate vaccine
Sponsors: Novartis; Novartis Vaccines
Recruiting - verified May 2012
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin

Condition: Hepatorenal Syndrome Type 1
Interventions: Drug: Terlipressin; Drug: Placebo
Sponsors: Ikaria Holdings Inc.; Ikaria Holdings Inc.
Recruiting - verified May 2012
Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Genetic: DNA ploidy analysis; Genetic: chromosomal translocation analysis; Genetic: cytogenetic analysis; Genetic: fluorescence in situ hybridization; Other: cytology specimen collection procedure; Other: flow cytometry; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Incidence of Cancer in Women at Increased Genetic Risk of Ovarian Cancer

Conditions: Breast Cancer; Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Other: questionnaire administration; Procedure: evaluation of cancer risk factors; Procedure: quality-of-life assessment; Procedure: study of high risk factors
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Condition: Type 2 Diabetes
Interventions: Drug: Dapagliflozin; Drug: Placebo matching Dapagliflozin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; AstraZeneca
Recruiting - verified November 2011
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo BI 10773 low dose; Drug: Placebo BI 10773 low dose; Drug: Placebo BI 10773 high dose; Drug: Placebo BI 10773 high dose; Drug: BI 10773 low dose; Drug: BI 10773 high dose
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified May 2012
RO4929097 in Treating Patients With Recurrent or Progressive Glioblastoma

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: gamma-secretase inhibitor RO4929097; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: adjuvant therapy; Procedure: neoadjuvant therapy; Procedure: therapeutic conventional surgery
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified May 2012
LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment

Condition: Breast Neoplasms
Interventions: Drug: BIBW 2992; Drug: trastuzumab; Drug: vinorelbine; Drug: vinorelbine
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers

Conditions: Acute Myelogenous Leukemia; Diffuse Large B-Cell Leukemia; Chronic Lymphocytic Leukemia; Follicular Lymphoma
Interventions: Drug: BMS-936564 (Anti-CXCR4); Drug: BMS-936564 (Anti-CXCR4)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified December 2011
Safety and Tolerability of Aripiprazole in Adolescents With Schizophrenia or Children and Adolescents With Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features.

Conditions: Adolescent Schizophrenia; Child or Adolescent Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features
Intervention: Drug: Aripiprazole
Sponsors: Otsuka Pharmaceutical Development & Commercialization, Inc.; Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified May 2012
Childhood Cancer Survivor Study

Condition: Cancer
Intervention:
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital; National Cancer Institute (NCI); Fred Hutchinson Cancer Research Center; Nationwide Children's Hospital; M.D. Anderson Cancer Center; University of Southern California; Children's Hospital Medical Center, Cincinnati
Recruiting - verified April 2012
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

Condition: Depression
Intervention: Drug: Armodafinil
Sponsors: Teva Pharmaceutical Industries; Cephalon
Recruiting - verified May 2012
Efficacy and Safety Trial of Transcranial Laser Therapy Within 24 Hours From Stroke Onset (NEST-3)

Condition: Acute Ischemic Stroke
Intervention: Device: NeuroThera® Laser System
Sponsors: PhotoThera, Inc; PhotoThera, Inc
Recruiting - verified April 2012
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension

Condition: Pulmonary Arterial Hypertension
Interventions: Drug: imatinib; Drug: imatinib
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012
Trial of Doxycycline to Reduce Sputum MMP-9 Activity in Adult Cystic Fibrosis (CF) Patients

Condition: Cystic Fibrosis
Interventions: Drug: Doxycycline; Other: placebo
Sponsors: University of Alabama at Birmingham; University of Alabama at Birmingham; Cystic Fibrosis Foundation
Recruiting - verified May 2012
High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer

Conditions: brca1 Mutation Carrier; brca2 Mutation Carrier; Breast Cancer
Interventions: Dietary Supplement: cholecalciferol; Other: placebo
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Younger Patients With Newly Diagnosed Ependymoma

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: vincristine sulfate; Other: clinical observation; Radiation: 3-dimensional conformal radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Study to Investigate CAL-101 in Combination With Chemotherapeutic Agents and CD20 mAb in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

Conditions: Indolent Non-Hodgkin's Lymphoma; Chronic Lymphocytic Leukemia; Mantle Cell Lymphoma
Interventions: Drug: CAL-101; Drug: Rituximab; Drug: Bendamustine; Drug: Ofatumumab; Drug: Fludarabine; Drug: Everolimus; Drug: Bortezomib; Drug: Chlorambucil
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified April 2012
Laquinimod Study in Systemic Lupus Erythematosus (SLE) Patients With Active Lupus Arthritis

Condition: Lupus Arthritis
Interventions: Drug: Laquinimod; Drug: Laquinimod; Other: Placebo
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries
Recruiting - verified May 2012
Study To Assess Fracture Healing With Sclerostin Antibody

Condition: Fracture Healing
Interventions: Drug: Placebo; Drug: AMG 785 140 mg; Drug: AMG785 70mg; Drug: AMG 785 210mg
Sponsors: Amgen; Amgen
Recruiting - verified April 2012
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl

Condition: Attention-Deficit/Hyperactivity Disorder
Interventions: Drug: Extended-release Guanfacine Hydrochloride; Other: Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified May 2012
Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy

Condition: Colorectal Cancer
Interventions: Biological: cetuximab; Biological: ramucirumab; Drug: irinotecan hydrochloride
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2012
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents

Condition: Arthritis, Psoriatic
Interventions: Drug: placebo; Drug: ustekinumab; Drug: ustekinumab; Drug: placebo; Drug: placebo; Drug: ustekinumab; Drug: ustekinumab; Drug: ustekinumab
Sponsors: Centocor, Inc.; Centocor, Inc.
Recruiting - verified April 2012
Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy

Condition: Acute Coronary Syndrome
Interventions: Drug: Otamixaban (XRP0673); Drug: Otamixaban matching placebo; Drug: Unfractionated Heparin; Drug: Unfractionated Heparin matching placebo; Drug: Eptifibatide; Drug: Eptifibatide matching placebo
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012
Immunotherapy Study for Surgically Resected Pancreatic Cancer

Condition: Pancreatic Cancer
Interventions: Biological: HyperAcute-Pancreas Immunotherapy; Drug: Gemcitabine; Radiation: 5FU Chemoradiation
Sponsors: NewLink Genetics Corporation; NewLink Genetics Corporation
Recruiting - verified May 2012
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)

Condition: Breast Cancer
Interventions: Drug: Placebo; Drug: Denosumab
Sponsors: Amgen; Amgen; Daiichi Sankyo Inc.
Recruiting - verified April 2012
Simvastatin Therapy for Moderate and Severe COPD

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: simvastatin; Drug: Placebo
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified April 2012
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

Condition: Rheumatoid Arthritis
Interventions: Drug: SAR153191 (REGN88); Drug: placebo
Sponsors: Sanofi-Aventis; Sanofi-Aventis; Regeneron Pharmaceuticals
Recruiting - verified May 2012
Long-Term Outcomes in HIV-Infected Infants, Children, and Adolescents

Condition: HIV Infections
Intervention:
Sponsors: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; International Maternal Pediatric Adolescent AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2012
A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+RO5072759 (GA101) in Patients With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)

Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: bendamustine; Drug: RO5072759
Sponsors: Genentech; Genentech; Roche Pharma AG
Recruiting - verified May 2012
Iontophoresis Delivery of Dexamethasone Phosphate for Non-infectious, Non-necrotizing Anterior Scleritis, Phase 1 Dose-varying Study

Condition: Non-infectious, Non-necrotizing Anterior Scleritis
Interventions: Drug: Dexamethasone Phosphate Ophthalmic Solution (EGP-437); Drug: Dexamethasone phosphate ophthalmic solution
Sponsors: University of Pennsylvania; John Kempen; FDA Office of Orphan Products Development; Eyegate Pharmaceuticals, Inc.
Recruiting - verified May 2012
Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma

Condition: Sarcoma
Interventions: Biological: cixutumumab; Biological: dactinomycin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: irinotecan hydrochloride; Drug: temozolomide; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Study of Intravenously Administered Tamiflu (Oseltamivir) in Patients Over 13 Years of Age With Influenza

Condition: Influenza
Interventions: Drug: Tamiflu; Drug: Tamiflu
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012
Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Septic Shock

Conditions: Septic Shock; Endotoxemia
Intervention: Device: TORAYMYXIN PMX-20R (PMX cartridge)
Sponsors: Spectral Diagnostics (US) Inc.; Spectral Diagnostics (US) Inc.
Recruiting - verified April 2012
Pilot Feasibility Study With Patients Who Are at High Risk For Developing Invasive Candidiasis in a Critical Care Setting (MK-0991-067)

Condition: Suspected Invasive Candidiasis
Interventions: Drug: caspofungin acetate; Drug: Comparator: placebo
Sponsors: Merck; Merck; Mycoses Study Group
Recruiting - verified May 2012
Adolescent Fibromyalgia Study

Condition: Fibromyalgia
Interventions: Drug: placebo; Drug: pregabalin (Lyrica)
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
Pregabalin In Adolescent Patients With Fibromyalgia

Condition: Fibromyalgia
Intervention: Drug: pregabalin
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
Global Demyelinating Disease Registry

Condition: Multiple Sclerosis
Intervention:
Sponsors: University of Alabama at Birmingham; University of Alabama at Birmingham; Consortium of Multiple Sclerosis Centers
Recruiting - verified April 2012
Treatment of Symptomatic Lumbar Internal Disc Disruption (IDD) With the Biostat® System

Conditions: Back Pain; Chronic Low Back Pain; Internal Disc Disruption; Degenerative Disc Disease
Interventions: Biological: Biostat System; Drug: Sodium Chloride Injection
Sponsors: Spinal Restoration, Inc.; Spinal Restoration, Inc.
Recruiting - verified May 2012
Stereotactic Radiation Therapy and Sorafenib in the Treatment of Hepatocellular Carcinoma

Conditions: Hepatocellular Carcinoma; Liver Cancer
Interventions: Drug: Sorafenib; Radiation: Stereotactic Body Radiotherapy (SBRT)
Sponsors: University of Alabama at Birmingham; University of Alabama at Birmingham; Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma
Recruiting - verified April 2012
Golimumab in Rheumatoid Arthritis Patients With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)

Conditions: Arthritis; Arthritis, Rheumatoid; Autoimmune Diseases
Interventions: Drug: golimumab or placebo; Drug: golimumab; Drug: golimumab or placebo; Drug: golimumab; Drug: golimumab or placebo
Sponsors: Centocor, Inc.; Centocor, Inc.; Merck
Recruiting - verified April 2012
Confirmatory Study of 17P Versus Vehicle for the Prevention of Preterm Birth in Women With a Previous Singleton Spontaneous Preterm Delivery

Condition: Preterm Birth
Interventions: Drug: Hydroxyprogesterone Caproate Injection, 250mg/mL; Drug: Vehicle
Sponsors: KV Pharmaceutical Company; KV Pharmaceutical Company; ResearchPoint Global
Recruiting - verified May 2012
Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma

Conditions: Lymphoma; Lymphoproliferative Disorder
Interventions: Other: biologic sample preservation procedure; Other: informational intervention
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients

Condition: Alzheimer Disease
Intervention: Drug: Bapineuzumab 0.5 mg/kg
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012
Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures

Condition: Partial Epilepsy
Interventions: Drug: Eslicarbazepine acetate; Drug: Eslicarbazepine acetate; Drug: Eslicarbazepine acetate
Sponsors: Bial - Portela C S.A.; Bial - Portela C S.A.; Sunovion
Recruiting - verified May 2012
Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: cediranib maleate; Drug: cilengitide; Other: enzyme-linked immunosorbent assay; Other: flow cytometry; Other: laboratory biomarker analysis; Procedure: magnetic resonance imaging
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified May 2012
Treatment Failure of Chlamydial Infection in Males and Females in Youth Correctional Facilities

Condition: C. Trachomatis
Interventions: Drug: Azithromycin; Drug: Doxycycline
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2012
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma

Conditions: Brain and Central Nervous System Tumors; Neurotoxicity
Interventions: Drug: temozolomide; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Pharmacokinetic Effects of New Antiretroviral Drugs on Children, Adolescents and Young Adults

Condition: HIV Infections
Interventions: Drug: Raltegravir (RAL); Drug: Atazanavir (ATV); Drug: Ritonavir (RTV); Drug: Tenofovir (TDF); Drug: Etravirine (ETV); Drug: Darunavir (DRV); Drug: Maraviroc (MVC); Drug: Lopinavir/ritonavir (LPV/r)
Sponsors: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; International Maternal Pediatric Adolescent AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2012
A Study In Patients Who Will Undergo Surgical Removal Of Non-Small Cell Lung Cancer To Evaluate Molecular Changes That Occur In Tumor Tissue After Short Term Exposure To PF-00299804

Condition: Non-Small Cell Lung Cancer (NSCLC)
Intervention: Drug: PF-00299804
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer

Condition: Head and Neck Cancer
Interventions: Biological: cetuximab; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Examining Benefits of HAART Continuation in Postpartum Mothers

Condition: HIV Infections
Intervention: Drug: Highly active antiretroviral therapy (HAART)
Sponsors: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; International Maternal Pediatric Adolescent AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2012
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine or Ovarian Cancer

Conditions: Ovarian Cancer; Sarcoma
Interventions: Drug: carboplatin; Drug: ifosfamide; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Trial to Assess Lacosamide as the First add-on Anti-epileptic Drug Treatment in Patients With Partial-onset Seizures

Condition: Partial Epilepsies
Intervention: Drug: Lacosamide
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified May 2012
Examining the Use of Non-Invasive Inhaled Nitric Oxide to Reduce Chronic Lung Disease in Premature Newborns

Condition: Bronchopulmonary Dysplasia
Interventions: Drug: Inhaled Nitric Oxide (iNO); Drug: Nitrogen (placebo)
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified May 2012
Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Biological: bevacizumab; Biological: cetuximab; Drug: carboplatin; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
An SGN-35 Trial for Patients Who Have Previously Participated in an SGN-35 Study

Conditions: Disease, Hodgkin; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin
Intervention: Drug: SGN-35
Sponsors: Seattle Genetics, Inc.; Seattle Genetics, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified April 2012
A Multicenter, Open-Label Study To Investigate The Safety And Pharmacokinetics Of Lacosamide In Children With Partial Seizures

Condition: Epilepsy
Intervention: Drug: Lacosamide
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified May 2012
An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: PF-02341066
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
A Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Cancer-related Pain

Conditions: Pain, Burning; Pain, Crushing; Pain, Migratory; Pain, Radiating; Pain, Splitting
Interventions: Drug: JNJ-42160443; Drug: Placebo
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2012
Efficacy of Combination Therapies for Gonorrhea Treatment

Condition: Gonococcal Infections
Interventions: Drug: Azithromycin; Drug: Gentamicin; Drug: Gemifloxacin
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified November 2011
Image-Guided Radiosurgery or Stereotactic Body Radiation Therapy in Treating Patients With Localized Spine Metastasis

Conditions: Metastatic Cancer; Pain
Interventions: Radiation: external beam radiation therapy; Radiation: image-guided radiation therapy; Radiation: radiosurgery; Radiation: stereotactic body radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias

Conditions: Leukemia-relapsed or Refractory; Cancer
Interventions: Drug: GSK1120212; Drug: GSK1120212
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012
Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma

Conditions: Chordoma; Desmoid Tumor; Sarcoma
Interventions: Genetic: reverse transcriptase-polymerase chain reaction; Other: biologic sample preservation procedure; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors

Condition: Brain and Central Nervous System Tumors
Intervention: Other: biologic sample preservation procedure
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Children With Sickle Cell Disease

Condition: Pneumococcal Conjugate Vaccine
Intervention: Biological: 13-valent Pneumoccocal Conjugate Vaccine
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Conditions: Atrial Fibrillation; Arrhythmia; Stroke Prevention; Mortality
Interventions: Device: Left atrial ablation; Drug: Rate or Rhythm Control Therapy
Sponsors: Mayo Clinic; Mayo Clinic; National Heart, Lung, and Blood Institute (NHLBI); St. Jude Medical; Biosense Webster, Inc.
Recruiting - verified April 2012
Eslicarbazepine Acetate Monotherapy Long Term Study

Condition: Epilepsy
Intervention: Drug: Eslicarbazepine acetate
Sponsors: Sunovion; Sunovion
Recruiting - verified April 2012
Study of AMG 785 in Tibial Diaphyseal Fractures Status Post Intramedullary Nailing

Condition: Fracture Healing
Interventions: Drug: AMG 785 210mg; Drug: AMG 785 70mg; Drug: AMG 785 140 mg; Drug: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified April 2012
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma

Condition: Neuroblastoma
Interventions: Genetic: fluorescence in situ hybridization; Genetic: gene expression analysis; Genetic: nucleic acid amplification; Genetic: polymerase chain reaction; Genetic: reverse transcriptase-polymerase chain reaction; Other: cytology specimen collection procedure; Other: flow cytometry; Procedure: biopsy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Sensory Processing in Subjects With Painful Bladder Syndrome

Condition: Painful Bladder Syndrome
Intervention: Other: Physical examination
Sponsors: University of Alabama at Birmingham; University of Alabama at Birmingham; Washington University School of Medicine
Recruiting - verified April 2012
Study of Kidney Tumors in Young Patients

Conditions: Kidney Cancer; Nonneoplastic Condition
Interventions: Genetic: loss of heterozygosity analysis; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Other: immunohistochemistry staining method; Procedure: computed tomography; Procedure: magnetic resonance imaging
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Collecting and Storing Biological Samples From Young Patients With Hodgkin's Lymphoma

Condition: Lymphoma
Intervention: Other: biologic sample preservation procedure
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Collecting and Storing Samples of Bone Marrow and Blood From Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma

Conditions: Leukemia; Lymphoma
Intervention: Other: biologic sample preservation procedure
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Collecting and Storing Samples of Blood and Tumor Tissue From Patients With Osteosarcoma

Condition: Sarcoma
Intervention: Other: biologic sample preservation procedure
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Collecting and Storing Tissue From Young Patients With Cancer

Condition: Cancer
Interventions: Genetic: DNA analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: biologic sample preservation procedure; Other: flow cytometry; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Collecting Tissue Samples From Patients With Leukemia or Other Blood Disorders Planning to Enroll in an ECOG Leukemia Treatment Clinical Trial

Conditions: Leukemia; Lymphoma
Intervention: Other: biologic sample preservation procedure
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer

Conditions: Leukemia; Neoplasm of Uncertain Malignant Potential; Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Other: cytology specimen collection procedure
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Collecting and Storing Biological Samples From Patients With Ewing Sarcoma

Condition: Sarcoma
Interventions: Other: biologic sample preservation procedure; Other: medical chart review
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme

Condition: Brain and Central Nervous System Tumors
Interventions: Biological: anti-PDGFR alpha monoclonal antibody IMC-3G3; Biological: ramucirumab
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI); ImClone LLC
Recruiting - verified April 2012
A Study of Ixabepilone as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer

Condition: Endometrial Cancer
Interventions: Drug: Ixabepilone; Drug: Doxorubicin; Drug: Paclitaxel
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified February 2012
Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease

Condition: Alzheimer's Disease
Interventions: Genetic: CERE-110: Adeno-Associated Virus Delivery of NGF; Procedure: Placebo Surgery
Sponsors: Ceregene; Ceregene; Alzheimer's Disease Cooperative Study (ADCS)
Recruiting - verified May 2012
Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Everolimus; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Conditions: Breast Cancer; Lung Cancer; Metastatic Cancer; Multiple Myeloma and Plasma Cell Neoplasm; Prostate Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Procedure: assessment of therapy complications
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Pilot Study of Tetomilast in Chronic Obstructive Pulmonary Disease (COPD) Associated With Emphysema

Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: tetomilast; Drug: placebo
Sponsors: Otsuka Pharmaceutical Development & Commercialization, Inc.; Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified May 2012
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia

Condition: Leukemia
Interventions: Drug: arsenic trioxide; Drug: cytarabine; Drug: idarubicin; Drug: mercaptopurine; Drug: methotrexate; Drug: mitoxantrone hydrochloride; Drug: tretinoin; Genetic: cytogenetic analysis; Genetic: polymerase chain reaction; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs

Condition: Epilepsy With Simple or Complex Partial Onset Seizures
Interventions: Drug: Eslicarbazepine acetate; Drug: Eslicarbazepine acetate
Sponsors: Sunovion; Sunovion
Recruiting - verified April 2012
Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Circumcised Men and Male-to-Female (MTF) Transgender Persons Who Have Sex With Men

Condition: HIV Infections
Interventions: Biological: DNA plasmid vaccine; Biological: Recombinant adenoviral serotype 5 (rAD5) vector vaccine; Biological: DNA vaccine placebo; Biological: HIV-1 recombinant adenovirus vaccine placebo
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); HIV Vaccine Trials Network
Recruiting - verified May 2012
Study of Immunotherapy to Treat Advanced Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Ipilimumab; Drug: Placebo
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified December 2011
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy

Conditions: Non-Small Cell Lung Cancer; Anemia; Cancer; Lung Cancer
Interventions: Drug: darbepoetin alfa 500 mcg Q3W; Drug: placebo
Sponsors: Amgen; Amgen
Recruiting - verified April 2012
Bendamustine With Irinotecan Followed by Etoposide/Carboplatin for Patients With Extensive Stage Small Cell Lung Cancer

Conditions: Small Cell Lung Cancer; Extensive Stage; Chemonaive
Intervention: Drug: Bendamustine, Irinotecan, Etoposide/Carboplatin
Sponsors: University of Alabama at Birmingham; University of Alabama at Birmingham; National Comprehensive Cancer Network
Recruiting - verified April 2012
Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine

Condition: Meningococcal Meningitis
Interventions: Other: Blood draw; Other: Blood draw; Other: Blood draw; Biological: Group IV; Biological: Group V
Sponsors: Novartis; Novartis Vaccines
Recruiting - verified May 2012
Anti-TNF Agents for the Treatment of Rheumatoid Arthritis

Condition: Rheumatoid Arthritis
Interventions: Drug: Etanercept; Drug: Adalimumab
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2012
An Open-label, Randomized, Multicenter Phase IIIb Study to Assess the Efficacy, Safety and Tolerance of BERIPLEX® P/N Compared With Plasma for Rapid Reversal of Coagulopathy Induced by Vitamin K Antagonists in Subjects Requiring an Urgent Surgical Procedure

Condition: Reversal of Coagulopathy
Interventions: Biological: Beriplex® P/N; Biological: Fresh frozen plasma
Sponsors: CSL Behring; CSL Behring
Recruiting - verified May 2012
Capecitabine, Gemcitabine, and Radiation Therapy in Treating Patients With Cholangiocarcinoma of the Gallbladder or Bile Duct

Conditions: Extrahepatic Bile Duct Cancer; Gallbladder Cancer
Interventions: Drug: capecitabine; Drug: gemcitabine hydrochloride; Procedure: adjuvant therapy; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)

Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Sitagliptin phosphate; Drug: Placebo
Sponsors: Merck; Merck; Duke Clinical Research Institute, Oxford Diabetes Trials Unit
Recruiting - verified May 2012
AngelMed for Early Recognition and Treatment of STEMI

Conditions: Acute Myocardial Infarction (AMI); Coronary Occlusion; Acute Coronary Syndrome
Intervention: Device: AngelMed Guardian System
Sponsors: Angel Medical Systems; Angel Medical Systems; Symbios Clinical
Recruiting - verified April 2012
Neuropsychological and Behavioral Testing in Young Patients With Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor (PNET)

Conditions: Brain and Central Nervous System Tumors; Chemotherapeutic Agent Toxicity; Cognitive/Functional Effects; Neurotoxicity; Psychosocial Effects of Cancer and Its Treatment; Radiation Toxicity; Therapy-related Toxicity
Interventions: Other: questionnaire administration; Procedure: cognitive assessment; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Study of Pemetrexed, Carboplatin and Bevacizumab in Patients With Nonsquamous Non-Small Cell Lung Cancer

Condition: Non-small Cell Lung Cancer
Interventions: Drug: Pemetrexed; Drug: Pemetrexed; Drug: Paclitaxel; Drug: Carboplatin; Biological: Bevacizumab; Biological: Bevacizumab
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2012
Using Alternative Implants for the Surgical Treatment of Hip Fractures (The FAITH Study)

Condition: Femoral Neck Fractures
Interventions: Device: Open reduction internal fixation (ORIF) with single sliding hip screw; Device: ORIF with multiple cancellous screws
Sponsors: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); Canadian Institutes of Health Research (CIHR); Stichting Nuts Ohra (SNO); Physicians Services Incorporated (PSI) Foundation
Recruiting - verified April 2012
A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION

Condition: Optic Neuropathy, Ischemic
Intervention: Drug: No intervention
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012
Study of Losartan in Pediatric Patients With Hypertension (MK-0954-337 AM4/AM5)

Condition: Hypertension
Intervention: Drug: losartan potassium
Sponsors: Merck; Merck
Recruiting - verified May 2012
Airway Epithelium Gene Expression: AEGIS II

Condition: Lung Cancer
Intervention: Device: Biomarker (not used as an intervention)
Sponsors: Allegro Diagnostics, Corp.; Allegro Diagnostics, Corp.; University of Pennsylvania; Columbia University; Temple University; Indiana University; University of Alabama at Birmingham; University of Missouri-Columbia; Louisiana State University Health Sciences Center in New Orleans; University of Wisconsin, Madison; Medical University of South Carolina; National Jewish Health; Overlake Hospital Bellevue WA; Pulmonary and Allergy Associates of New Jersey; Pulmonary Associates of Arizona; William Jennings Bryan Dorn VA Medical Center; Virginia Commonwealth University; Jamaica Hospital Medical Center; North Florida/South Georgia Veterans Health System; Steward St. Elizabeth; University of California, Davis; Yale University Medical Center; The Cleveland Clinic; Johns Hopkins University
Recruiting - verified May 2012
Safety and Exploratory Efficacy of Kanglaite Injection in Pancreatic Cancer

Condition: Pancreatic Cancer
Interventions: Drug: Kanglaite Injection plus gemcitabine; Drug: Gemcitabine
Sponsors: KangLaiTe USA; KangLaiTe USA
Recruiting - verified January 2012
Lamictal as Add-on Treatment for Bipolar I Disorder in Pediatric Patients

Condition: Bipolar Disorder
Intervention: Drug: lamictal
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012
Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy

Conditions: Brain and Central Nervous System Tumors; Childhood Germ Cell Tumor; Extragonadal Germ Cell Tumor; Liver Cancer; Neuroblastoma; Ototoxicity; Ovarian Cancer; Sarcoma
Interventions: Drug: sodium thiosulfate; Procedure: examination
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E)

Condition: Huntington's Disease
Interventions: Drug: Creatine Monohydrate (HD-02); Drug: Placebo
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; University of Rochester; National Center for Complementary and Alternative Medicine (NCCAM)
Recruiting - verified April 2012
Effectiveness of Long-term Oxygen Therapy in Treating People With Chronic Obstructive Pulmonary Disease (The Long-term Oxygen Treatment Trial [LOTT])

Condition: Chronic Obstructive Pulmonary Disease
Intervention: Behavioral: Supplemental oxygen therapy
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); National Heart, Lung, and Blood Institute (NHLBI); Centers for Medicare and Medicaid Services
Recruiting - verified April 2012
Phase III Lucanix™ Vaccine Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line Chemotherapy

Conditions: Lung Neoplasm; Carcinoma Non-small Cell Lung Cancer Stage IIIA; Carcinoma Non-small Cell Lung Cancer Stage IIIB; Carcinoma Non-small Cell Lung Cancer Stage IV
Interventions: Biological: Lucanix™; Other: Placebo Comparator
Sponsors: NovaRx Corporation; NovaRx Corporation
Recruiting - verified April 2012
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients

Condition: Alzheimer Disease
Interventions: Drug: bapineuzumab; Drug: bapineuzumab; Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012
Bacterial Vaginosis Home Screening to Prevent STDs

Condition: Bacterial Vaginosis
Interventions: Other: No Intervention; Drug: Metronidazole
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified November 2011
Prospective Observational Epidemiologic Study of Maraviroc's Safety

Condition: Human Immunodeficiency Virus
Interventions: Drug: Maraviroc along with an optimized background antiretroviral drug regimen; Drug: Optimized background antiretroviral drug regimen without maraviroc
Sponsors: ViiV Healthcare; ViiV Healthcare; Pfizer
Recruiting - verified May 2012
Safety and Effectiveness of Atorvastatin in HIV Infected Children and Adolescents With Hyperlipidemia

Conditions: HIV Infections; Hyperlipidemia
Intervention: Drug: Atorvastatin
Sponsors: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; International Maternal Pediatric Adolescent AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified May 2012
Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer

Condition: Esophageal Cancer
Interventions: Biological: cetuximab; Drug: cisplatin; Drug: paclitaxel; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System

Condition: Brain and Central Nervous System Tumors
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: etoposide phosphate; Drug: methotrexate; Drug: thiotepa; Drug: vincristine sulfate; Genetic: mutation analysis; Other: immunohistochemistry staining method; Procedure: autologous hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: 3-dimensional conformal radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism

Condition: Venous Thrombosis
Interventions: Drug: Enoxaparin; Drug: warfarin; Drug: Placebo for apixaban; Drug: Placebo for enoxaparin; Drug: Placebo for warfarin; Drug: apixaban
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Pfizer
Recruiting - verified October 2010
Nepicastat for Posttraumatic Stress Disorder (PTSD) in OIF/OEF Veterans

Condition: Posttraumatic Stress Disorder
Interventions: Drug: Nepicastat; Drug: Placebo
Sponsors: Tuscaloosa Research & Education Advancement Corporation; Tuscaloosa Research & Education Advancement Corporation; Biotie Therapies Inc.; Ralph H. Johnson VA Medical Center; Baylor College of Medicine; Department of Veterans Affairs; San Diego Veterans Healthcare System
Recruiting - verified April 2012
Three Different Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide

Condition: Lung Cancer
Interventions: Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI); Radiation Therapy Oncology Group
Recruiting - verified May 2012
Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi

Conditions: Aspergillosis; Invasive Fungal Infections
Intervention: Drug: isavuconazole
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc; Basilea Pharmaceutica
Recruiting - verified May 2012
Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism

Condition: Venous Thrombosis
Interventions: Drug: Apixaban; Drug: Placebo
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Pfizer
Recruiting - verified August 2010
Defibrotide for Patients With Hepatic Veno-occlusive Disease (VOD): A Treatment IND Study

Condition: Hepatic Veno-Occlusive Disease
Intervention: Drug: Defibrotide
Sponsors: Gentium SpA; Gentium SpA
Recruiting - verified May 2012
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Condition: Multiple Sclerosis
Interventions: Drug: Teriflunomide (HMR1726); Drug: Placebo
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012
Prospective Evaluation of the Effects of Topical Therapy With Sulfamylon® For 5% Topical Solution on Autograft Healing in Subjects With Thermal Injuries Requiring Meshed Autografts: A Comparison to a Historical Control Group

Condition: Burns
Intervention: Drug: Sulfamylon® (mafenide acetate) For 5 % Topical Solution
Sponsors: Mylan Bertek Pharmaceuticals; Mylan Bertek Pharmaceuticals; Mylan Pharmaceuticals
Recruiting - verified April 2012
Coenzyme Q10 in Huntington's Disease (HD)

Condition: Huntington's Disease
Interventions: Drug: coenzyme Q10; Other: placebo
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; National Institute of Neurological Disorders and Stroke (NINDS); University of Rochester
Recruiting - verified May 2012
Aprotinin US Special Access Protocol

Condition: Postoperative Hemorrhage
Intervention: Drug: Aprotinin (Trasylol, BAYA0128)
Sponsors: Bayer; Bayer
Available - verified April 2012
Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Conditions: Crohn's Disease; Ulcerative Colitis; Inflammatory Bowel Diseases
Interventions: Drug: conventional systemic agents; Biological: infliximab; Biological: Biological therapies other than infliximab
Sponsors: Centocor Ortho Biotech Services, L.L.C.; Centocor Ortho Biotech Services, L.L.C.
Recruiting - verified May 2012
Combination Chemotherapy With or Without Lestaurtinib in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Drug: asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: etoposide; Drug: lestaurtinib; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: methylprednisolone; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma

Condition: Retinoblastoma
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: thiotepa; Drug: vincristine sulfate; Procedure: autologous bone marrow transplantation; Procedure: autologous hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Trial to Demonstrate the Efficacy and Safety of Conversion to Lacosamide Monotherapy for Partial-onset Seizures

Condition: Epilepsy
Interventions: Drug: Lacosamide; Drug: Lacosamide
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified April 2012
Psoriasis Longitudinal Assessment and Registry (PSOLAR)

Conditions: Psoriasis; Arthritis, Psoriatic
Interventions: Biological: ustekinumab; Biological: Biological therapies other than infliximab and ustekinumab; Drug: conventional systemic agents; Biological: infliximab
Sponsors: Centocor Ortho Biotech Services, L.L.C.; Centocor Ortho Biotech Services, L.L.C.
Recruiting - verified May 2012
Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Procedure: therapeutic thoracoscopy; Procedure: videothoracoscopy
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI); Radiation Therapy Oncology Group; American College of Surgeons; Southwest Oncology Group
Recruiting - verified April 2012
Safety and Effectiveness of Raltegravir (MK-0518) in Treatment-Experienced, HIV-Infected Children and Adolescents

Condition: HIV Infections
Interventions: Drug: Raltegravir (MK-0518); Drug: Raltegravir (MK-0518); Drug: Raltegravir (MK-0518)
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified April 2012
Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin

Conditions: Ototoxicity; Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Procedure: management of therapy complications
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Open-Label Extension Study Of Safety And Tolerability Of Pregabalin In Pediatric Patients With Partial-Onset Seizures

Condition: Epilepsies, Partial
Intervention: Drug: Pregabalin
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
Gemcitabine After Surgery in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer

Condition: Bladder Cancer
Interventions: Drug: gemcitabine hydrochloride; Other: placebo
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Safety, Tolerability, and Pharmacokinetic Study of Pregabalin in Pediatric Patients With Partial Onset Seizures

Condition: Epilepsies, Partial
Interventions: Drug: Placebo; Drug: Pregabalin
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease

Conditions: Anemia; Chronic Kidney Disease; Kidney Disease
Interventions: Drug: darbepoetin alfa QW; Drug: darbepoetin alfa Q2W
Sponsors: Amgen; Amgen
Recruiting - verified April 2012
Long-Term Effectiveness And Safety Of CP-690,550 For The Treatment Of Rheumatoid Arthritis

Condition: Arthritis, Rheumatoid
Interventions: Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections

Conditions: Mycoses; Candidiasis, Invasive; Candidemia
Interventions: Drug: Isavuconazole; Drug: Caspofungin; Drug: Voriconazole
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc; Basilea Pharmaceutica
Recruiting - verified May 2012
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

Conditions: Leukemia; Lymphoma
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: nelarabine; Drug: pegaspargase; Drug: prednisone; Drug: thioguanine; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor

Condition: Brain and Central Nervous System Tumors
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: isotretinoin; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Repository for Inherited Eye Diseases

Conditions: Retinitis Pigmentosa; Inherited Ophthalmic Diseases
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Eye Institute (NEI)
Recruiting - verified June 2011
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial

Conditions: Heart Failure; Anemia; Cardiovascular Disease; Ventricular Dysfunction; Congestive Heart Failure
Interventions: Drug: Darbepoetin alfa; Drug: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified April 2012
Vision Testing in Patients With Partial Seizures Receiving Either Lyrica or Placebo

Condition: Epilepsies, Partial
Interventions: Drug: Lyrica (pregabalin); Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012
Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen

Conditions: Arthritis, Rheumatoid; Osteoarthritis
Interventions: Drug: celecoxib; Drug: Ibuprofen; Drug: Naproxen
Sponsors: Pfizer; Pfizer; The Cleveland Clinic
Recruiting - verified May 2012
EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer

Condition: Neoplasms, Breast
Intervention: Drug: lapatinib + capecitabine
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012
Radiation Therapy in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer

Condition: Breast Cancer
Interventions: Radiation: 3-dimensional conformal accelerated partial breast irradiation; Radiation: brachytherapy; Radiation: whole breast irradiation
Sponsors: National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI); Radiation Therapy Oncology Group; Southwest Oncology Group
Recruiting - verified May 2012
Prenatal and Postnatal Studies of Interventions for Prevention of Mother-To-Child Transmission

Conditions: HIV Infections; Pregnancy Complications, Infectious
Intervention: Behavioral: Adherence assessment
Sponsors: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; International Maternal Pediatric Adolescent AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified May 2012
Isotretinoin With or Without Monoclonal Antibody, Interleukin-2, and Sargramostim Following Stem Cell Transplantation in Treating Patients With Neuroblastoma

Condition: Neuroblastoma
Interventions: Biological: aldesleukin; Biological: monoclonal antibody Ch14.18; Biological: sargramostim; Drug: isotretinoin
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012